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Preface 
 
The first chapter of this PhD thesis is a brief introduction about the complexity of cancer 
genetics and biology. Furthermore it describes the two anticancer approaches of interest: 
DNA G-quadruplex secondary structures as targets for small molecules and tumor-homing 
peptides as tools for drug delivery into tumors. 
 
The second chapter reports the first project, which has been focused on the development 
of diimidazopyrimidine hydrazones, as small molecules able to bind DNA G-quadruplex 
structures, and potential antitumor agents.  
The work has been carried out under the supervision of Prof. Alessandra Locatelli at the 
Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of 
Bologna (Italy).  
 
The third chapter describes the second project, based on the synthesis of NGR tumor-
homing peptide derivatives and on the investigation of the structural requirements for 
effective tumor homing targeting.  
This research has been developed as PhD visiting student in the research group led by 
Prof. Matteo Zanda at the Institute of Medical Sciences, University of Aberdeen (Scotland, 
UK).  
 
The experimental procedures for the chemical synthesis and biological evaluation are 
reported in the fourth chapter of the thesis. 
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Abstract 
 
In anticancer drug discovery DNA secondary structures, called G-quadruplexes (G4s), 
emerged as targets of interest, owing to their localization in crucial positions of the 
genome, such as in telomers and oncogene promoter regions. It has been widely 
accepted that G4 stabilization by small molecules at these levels, may represent a realistic 
anticancer strategy. Since a diimidazo[1,2-a:1,2-c]pyrimidine bis-guanylhydrazone 
derivative was found to be a potent stabiliser of several quadruplex DNAs over duplex 
DNA, a library of analogues was designed and synthesized to shed light on the structural 
requirements for G4 binding. The newly synthesized hydrazones were evaluated for their 
ability to stabilize several G4 with different topology and also for their antiproliferative 
activity. In particular the most promising compound of the series showed the capability to 
selectively stabilize a specific G4 structure and to inhibit cancer cell growth in the 
nanomolar range. 
Tumor-homing peptides have been considered promising tools for imaging and therapy of 
tumors over-expressing their target ligand. In this context, the cyclic CNGRC peptide has 
been extensively used as tumor-homing carrier for its ability to specifically recognise 
aminopeptidase N (APN/CD13), a zinc-dependent ectoenzyme, upregulated in tumor 
blood vessels undergoing angiogenesis and in the majority of cancer cells. Considering the 
potential of APN-directed tumour homing strategies and taking into account the recently 
reported crystal structure of porcine APN complexed with cCNGRCG, a library of C-
terminus and N-terminus functionalized cCNGRC peptides was designed and synthesized 
with the aim to confirm the importance of N-terminal amine group of the cCNGRC in the 
APN binding. The synthesized peptides were assayed for their ability to inhibit APN in 
vitro. The C-terminus was identified as the right conjugation site of the cCNGRC peptide, 
which was consequently conjugated with a fluorescent probe for APN imaging studies in 
cancer cells.  
6 
 
 
CHAPTER 1 
1. INTRODUCTION 
1.1. Cancer statistics at a glance 
Cancers are among the leading causes of morbidity and mortality worldwide, with 
approximately 14 million new cases and 8.2 million cancer related deaths in 2012 (World 
Cancer Report 2014).  
According to Cancer Statistics 2016 by Siegel et al., over the past 3 decades, the 5-year 
relative survival rate for all cancers combined has increased 20 percentage points in 
United States.1  
Progress in cancer survival has been most rapid particularly for hematopoietic and 
lymphoid malignancies owing to improved treatment protocols. The discovery and the 
application of targeted therapies, such as the use of BCR-ABL tyrosine kinase inhibitors 
(e.g.: imatinib) allowed that survival for patients with chronic myeloid leukemia increased 
from 31% in the early 1990s to 63% during 2005 to 2011.2 
Despite these considerable progresses, death rates are increasing for cancers of liver, 
pancreas and uterine corpus. The advances in both diagnosis and therapy of liver and 
pancreatic cancers are proceeding more slowly. As a consequence these cancer types are 
two of the most fatal cancers in adults. Moreover, brain cancer represents the leading 
cause of cancer death in children and adolescents.1 
The fight against cancer still requires intensive clinical and basic research. 
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1.2. Cancer: an “evolutionary process” 
Cancers can be seen as the result of a Darwinian process occurring among cell 
populations. Indeed, analogous to what happens in the origins of species, cancer 
development is based on two constitutive processes: the acquisition of heritable genetic 
mutations in single cells and the natural selection resulting in phenotypic diversity. Cells 
carrying deleterious mutations, which acquire the capability to proliferate and survive 
even in stress conditions, are “selected” in cancer pathogenesis. A cancer cell descends 
from the fertilized egg, carrying a copy of its diploid genome; however, the DNA sequence 
of a cancer cell genome acquires substantial somatic differences from its progenitor 
fertilized egg (Fig. 1.1).3 
 
 
Figure 1.1. Mitotic cell divisions from the fertilized egg to a cancer single cell.3 
 
Somatic mutations in a cancer genome include base substitutions; insertions or deletions 
of DNA segments and DNA rearrangements. In addition, the cancer cell may have 
acquired completely new DNA sequences from exogenous sources, such as viruses (e.g.: 
human papilloma virus, Epstein Barr virus).4 
DNA in normal cells is continuously damaged by mutagens. Those damages that mislead 
the DNA reparation machinery, may be turned into fixed mutations. The mutation rates 
of each somatic mutation differ among the several structural classes, they also vary 
among cell tipes and increase upon mutagen exposure. For example tobacco smoke 
carcinogens exposure has been associated with prevalence of G –>T transversions in TP53 
gene found in lung cancer.5 
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However not all acquired somatic abnormalities have a central role in cancer 
development. The so-called ‘driver mutations’ are those effectively responsible of 
oncogenesis.3 A high number of these driver mutations and altered cancer genes have 
been identified so far. Some of the implicated cancer genes, such as TP53 and KRAS are 
frequently mutated in different cancer types, whereas others are specific for one cancer 
type (www.sanger.ac.uk/genetics/CGP/cosmic). 
Cancer genome may acquire also epigenetic changes responsible of alterations in 
chromatin structure and gene expression. Even cancer epigenetic abnormalities can be 
subjected to natural selection; they confer phenotypic plasticity, which results in cellular 
heterogeneity and tumor progression. Epigenetic gene regulation mechanisms include 
histone modifications, which play critical roles in reprogramming a cell's phenotype in 
response to environmental changes.6 
Somatic mutations within mitochondrial DNA have been also reported in many tumors. 
However, further studies are needed to clarify the functional significance of specific 
mitochondrial mutations in cancer progression.7 
  
9 
 
 
1.3. “Cancer hallmarks” 
Tumors have to be considered not as masses of proliferating cells, but as complex tissues 
composed of various cell types. Normal cells are recruited to form tumor-associated 
stroma, thus playing active roles in tumorigenesis. Therefore the biology of a tumor can 
be understood by studying both the specialized cell types and the ‘‘tumor 
microenvironment’’ (Fig. 1.2).  
 
 
Figure 1.2. The cells of the tumor microenvironment.8  
 
Hanahan and Weinberg defined ‘cancer hallmarks’ as the capabilities that cells 
progressively acquire to become tumorigenic and consequently malignant (Fig. 1.3).8,9 
These hallmarks of cancer together constitute an organizing principle which can be used 
for understanding the complexity of cancer biology and the diversity of neoplastic 
diseases. Cancer cells can acquire the capability to sustain proliferative signaling by 
producing growth factors, or alternatively by sending signals to normal cells of the tumor 
associated stroma.10 Growth factors are able to bind cell-surface tyrosine kinase 
receptors, thus activating intracellular signalling pathways that regulate progression 
through the cell cycle as well as cell growth.11 
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Figure 1.3. Hallmarks of cancer.8  
 
Moreover the levels of receptor proteins expressed on cancer cell surface, are often 
elevated and as a consequence, cells become hyperresponsive to growth factors. In 
addition somatic mutations in certain human tumors result in constitutive activation of 
signalling pathways (i.e.: mutations on phosphoinositide 3-kinase (PI3-kinase) 
hyperactivate mitogen activated Akt/PKB pathways).12 
In addition cell proliferation is sustained because tumor suppressor genes responsible of 
the negative regulation of cell proliferation are subjected to mutations in cancer cells. 
Prototypical tumor suppressors encode the RB (retinoblastoma-associated) and TP53 
proteins that operate within regulatory circuits, regulating the cell fate, leading to cell 
proliferation, or, alternatively, activating senescence and apoptotic programs.13 One of 
the strategies, adopted by tumour cells to circumvent apoptosis, is the loss of TP53 tumor 
suppressor function.14  
Moreover cancer cells undergo cell immortalization, thanks to the telomerase activity, 
consisting in the inhibition of the progressive telomere erosion that occurs after each cell 
cycle.15 
When necrotic cell death occurs in the context of a tumour, proinflammatory signals are 
released into the tissue microenvironment, and inflammatory cells are recruited,16 thus 
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resulting in increased angiogenesis, cancer cell proliferation, and invasiveness. Cancer 
cells have also the capability of evading the elimination by immune cells.17  
Like normal tissues, tumors require nutrients and oxygen and they need also to evacuate 
metabolic wastes and carbon dioxide. To this end, the angiogenesis process is of crucial 
importance to built the necessary tumor-associated vasculature.18  
Reprogramming of cellular energy metabolism is another capability acquired by tumours 
in order to support continuous cell growth and proliferation. Glucose uptake and glicolytic 
pathway are markedly increased in many human tumors, in response of activated 
oncogenes (e.g.: RAS, MYC) and mutant tumor suppressors (e.g.: TP53).19 Glycolysis can 
be accentuated under hypoxia; both RAS oncoprotein and hypoxia can independently 
increase the levels of two transcription factors HIF1-α and HIF2-α, responsible of 
glycolysis upregulation.20  
Cancer cells acquire also the capability to attach to other cells and to the extracellular 
matrix (ECM) proteins, in order to invade tissues. Local invasion is followed by 
intravasation of cancer cells into blood and lymphatic vessels, consequent extravasation 
into and colonization of distant organs: this multistep process represents the ‘invasion-
metastasis cascade’ of malignant tumors.21 
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1.4. Small molecules targeting DNA: past and future directions 
 
Figure 1.4. Classes of DNA-interactive agents.22  
 
Research before and during World War II led to the comprehension that nitrogen 
mustards were able to exert anticancer effects by alkylating DNA, showing a very high 
reactivity.23 Therefore DNA started to be perceived as target for therapeutic intervention 
of cancer and, as a result, a high number of the developed anticancer drugs target DNA 
with different mechanism of action (Fig. 1.4).22 
Among the synthesized alkylating agents, the aromatic mustards such as chlorambucil 
and mephalan (Fig. 1.5) are the most effective ones with the tendency to crosslink the 
two complementary strands of DNA.24  
Conversely the agent cisplatin (Fig. 1.5) causes crosslink within a strand of DNA, by 
binding covalently to adjacent guanines.25 Although showing side effects, which can be 
overcome by site-specific delivery, some cancers, such as the testicular one, showed a 
good sensitivity to this drug. 
It was surprising that the antibiotic doxorubicin (Fig. 1.5), known as non-specific DNA 
intercalating agent,26 would have shown higher selectivity for cancer cells than normal 
cells. Afterwards it was discovered that doxorubicin exerts its anticancer activity by 
inducing topoisomerase II-associated strand breaks.27 The selectivity for cancer cells 
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might be dependent on the elevated levels of the DNA associated topoisomearase II in 
these cells. However these features are counterbalanced by high toxicity and generation 
of resistance mechanisms. 
 
 
Figure 1.5. Chemical structures of DNA-interactive drugs. 
 
To overcome the toxicity issues of unspecific cytotoxic drugs, much attention was focused 
on the development of more selective targeted agents. 
A noteworthy example is the success of Gleevec against the tyrosine kinase domain of the 
abl kinase in chronic myelogenous leukaemia (CML).28 However kinase inhibitors and 
other targeted agents show much less effect in solid tumors; even in CML, mutations in 
the ATP binding site of the abl kinase led to resistance to Gleevec. Therefore, although 
the therapeutic window of cytotoxic agents is very narrow, these agents are still 
employed for the management of tumors and DNA is still considered an interesting target 
for therapeutic intervention in cancer.29 
There has been much effort towards the design of DNA sequence-specific molecules that 
can modulate transcription of particular genes, which would not have the disadvantage of 
generating resistance at the protein level. Sequence-specific molecules have to recognise 
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sequences of ca 16–20 nucleotides, available through the polyamide approach by Dervan 
and co-workers,30 and however they have not yet emerged as potential therapeutic 
agents. 
An alternative and more realistic approach is to target specific DNA secondary sequences, 
called G-quadruplex. Since these DNA secondary structures found in guanine rich 
sequences of DNA, were observed, and their biological roles were proposed, they have 
been considered a new class of molecular targets for DNA-interactive compounds.31  
The research community showed great interest in these DNA structures because targeting 
them may have the advantage to combine high target selectivity with the development of 
small-drug-like molecules.32  
In contrast to traditional duplex DNA binding agents, quarfloxin (Fig. 1.6), a synthetic G4 
ligand which entered clinical trials, showed no toxicity and appeared to be well 
tolerated.33 
N
O
O
F
N
N
H
N
N
O
N
Quarfloxin  
Figure 1.6. Chemical structure of the G-quadruplex ligand in clinical trials. 
 
In addition, DNA interactive drugs may be used in combination with agents that target 
molecular receptors to increase selectivity for cancer cells and to reduce side effects on 
healthy cells. Therefore there are several reasons to expect DNA G-quadruplex to be 
considered a target of clinical interest for cancer treatment.  
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1.5. Tumor-homing peptides as vehicles for cancer therapeutics and 
diagnostics 
 
Figure 1.7. Tumor homig peptides journey.34  
 
Recent approaches in anticancer drug design aim to target tumour microenvironment, 
particularly the tumor vasculature.35 Indeed a body of evidence demonstrate that tumour 
vessels have unique expression profile of surface protein and for this reason they may 
represent the ideal target to selectively deliver anticancer drugs into tumours.36 
Arap, Pasqualini et Ruoslahti identified by means in vivo phage display three peptide 
motifs capable of homing to tumor vasculature in mice bearing breast carcinoma 
xenografts: an RGD (arginine-glycine-aspartic acid) peptide motif,37 a GSL (glycine-serine-
leucine) motif and a NGR (asparagine-glycine-arginine) motif.38 
These peptide ligands are known as tumor homing peptides (THPs) for their ability to 
specifically bind tumor vasculature and consequently to accumulate in the tumor tissue. 
These THPs have emerged as promising tools to detect tumor in vivo and to deliver 
anticancer drugs specifically into tumor site, reducing side effects on healthy cells. THPs-
based therapy may overcome the disadvantages associated with mono-therapy, such as 
drug sensitivity and resistance, pharmacokinetics and solubility issues. Considering the 
potential of THPs, the interest in this field grew esponentially and phage display 
technology has been extensively applied to identify peptides with homing properties 
towards various cancer types. Preclinical studies of many THPs-based agents are ongoing, 
and, interestingly, some of them have been submitted to clinical evaluation (Fig. 1.7).34  
Indeed, both RGD and NGR peptides have already entered clinical trials. Cilengitide (Fig. 
1.8), a salt of a cyclized RGD pentapeptide acting as an integrin antagonist, is the first 
RGD-peptide based therapy in phase I, II, and III clinical trials for several cancers.39  
16 
 
 
 
Figure 1.8. RGD and NGR-based agents in clinical trials. 
 
Besides, the tracer [18F]-galacto-RGD can be used for non invasive PET imaging of αvβ3 
integrin expression in cancer.40  
As far as NGR-based agents are concerned, NGR peptide combined with hTNF-α (Fig. 1.8) is 
currently in phase III clinical trials for malignant pleural mesotelioma 
(www.clinicaltrials.com).  
In this scenario the development of hybrid conjugates in which one component is a NGR 
containing tumour-homing peptide acting as a carrier which targets specifically tumour 
vessels, while the other one may be the active agent appears as a promising and realistic 
anticancer strategy. Also NGR might be derivatized with molecular probes for early tumor 
diagnosis and tumor angiogenesis detection and monitoring upon therapy. 
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1.6. Aim of the thesis 
Since genomic alterations and their phenotypic expression in cancer are unique for each 
patient, replacing unspecific cytotoxic therapeutics with novel and personalized cancer 
therapies, represent the challenges for oncology research.  
The targeting cancer drugs developed toward specific molecular targets are characterized 
by less nonspecific toxicity with respect to unspecific cytotoxic drugs. Since they inhibit 
one key pathway in a tumor, it may not completely sufficient to impair a hallmark 
capability, allowing some cancer cells to survive with residual function. Tumor cells can 
respond by adaptation to the current therapy, through mutation, epigenetic 
reprogramming or remodelling of the stromal microenvironment, in order to establish the 
functional capability or to reduce their dependence on a particular hallmark capability.8 
It may become possible to target several cancer capabilities to prevent adaptive 
resistance that cancer can develop in response to therapy. Different strategies need to be 
explored in the search of new anticancer agents in order to obtain more effective 
therapies for human cancer. 
The aim of the present work is focused on two different approaches potentially useful in 
the clinical management of cancer.  
The first one is based on the assumption that DNA secondary structures, known as G-
quadruplexes, represent interesting targets for therapeutic intervention in cancer. In 
particular the stabilization by small molecules of these structures, found in crucial 
positions of the genome, is perceived as a promising anticancer strategy.  
The project was based on the extension of a class of hydrazones, previously reported by 
Locatelli and co-workers, as G-quadruplex selective binders.41 The design, the synthesis 
and the G-quadruplex binding properties of a library of diimidazo[1,2-a:1,2-c]pyrimidine 
bis-guanylhydrazone derivatives and analogues will be described in the second chapter of 
this elaborate. 
The second approach is focused on the development of hybrid drugs containing a 
tumour-homing peptide which targets specifically tumour vessels and that can be used as 
drug delivery tool. In the context of NGR-tumour homing peptides, the cyclic CNGRC 
peptide represents a valid carrier to deliver anticancer drugs or imaging probes into 
tumors.38  
18 
 
 
The structural requirements of the NGR peptide for effective tumour homing through 
APN targeting were investigated in this project. The design, the synthesis and the 
biological evaluation of differently functionalized cCNGRC peptide derivatives will be 
reported in the third chapter of the thesis.  
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CHAPTER 2 
2. Design and synthesis of novel hydrazone 
derivatives of diimidazo[1,2a-1,2c]pyrimidine as 
selective G-quadruplex binders and promising 
anticancer drug candidates 
2.1. Background 
2.1.1. DNA G-quadruplexes: topology, structure and biological roles 
 
G-quadruplexes (G4s) are higher-order nucleic acid arrangements which arise from 
guanine-rich nucleic acid sequences. G4s are built by tetrads of Hoogsten hydrogen-
bonded guanine bases (G-quartets), that stack together in the manner of base pairs in 
duplex nucleic acids, showing, however, important differences: they constitute a four 
stranded structure in which sodium or potassium ions are held centrally between 
quartets and are coordinated to the O6 substituent of each guanine base. The G-quartets 
are held together by loops positioned on the exterior. Grooves, formed between the 
loops, are bounded by negatively charged phosphodiester backbones (Fig. 2.1).42–44  
 
 
 
Figure 2.1. a) Stick representation of a guanine G-quartet with hydrogen bonds shown as dashed lines. b) Cartoon 
representation of a quadruplex (PDB code 1JPQ).45  
 
a) b) 
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G-quadruplexes adopt several topologies depending on loop length and sequence, and 
show structural differences, regarding stoichiometry, chains orientation, loops geometry 
and glycosidic conformation. G4s can be formed from (i) a single strand, (unimolecular 
quadruplexes), having the general sequence Ga Xn Gb Xo Gc Xp Gd where Ga−d represent 
short guanine (G) tracts and Xn−p represent intervening “loop” connections; (ii) two 
strands (bimolecular quadruplexes); (iii) three or four strands (tetramolecular 
quadruplexes).44,46 The four phosphodiester chains of the quadruplex can be parallel or 
anti-parallel, depending on the type of loop connecting them. Parallel strands require a 
connecting loop to link the bottom G-tetrad with the top G-tetrad, resulting in propeller 
type loops.47,48 In anti-parallel quadruplexes lateral (edge-wise)49 and diagonal loops50 
have been observed to link adjacent G-strands and opposite G-strands respectively. 
Parallel G4s have all guanosines in an anti-conformation, while the anti-parallel ones have 
shown both syn- and anti-conformations. All G4s have the common feature of a core of at 
least two stacked G-quartets, a central ion channel and four grooves.44 The stability of G-
quadruplexes strongly depends on monovalent cations. The guanine O6 oxygen atoms 
create a strong negative channel in which cations are located in a manner dependending 
on the nature of the ion (Fig. 2.1). Na+ can be located in plane with a G-quartet, or 
between two G-quartets, while the larger K+ ion tends to have a central position between 
two proximal guanine tetrads.51 
A number of quadruplexes have been characterized by biophysical methods (circular 
dichroism, fluorescence spectroscopy, NMR or crystallography), by either as native 
structures or as small-molecule complexes.52  
G-quadruplexes have been found in several G-rich regions, such as human telomers,53 
oncogene promoters54 and 5’-untraslated regions (UTR).55 
The greatest concentration of G-quadruplex motifs has been found in telomers at 
chromosome ends, owing to the presence of the hexanucleotide repeat sequence 
d(TTAGGG) and G-quadruplex formation at this level may be involved in telomere 
mantainance.56,57 The telomeric G4s display a variety of folds. 2D-NMR studies in dilute 
solution in presence of K+ ion revealed several folds with antiparallel strands, including 
hybrid topologies in which three of the four backbone strands are parallel and the fourth 
is in the antiparallel direction (Fig. 2.2 a),58–60 while under crowding and high 
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concentration conditions the parallel form is prevalent.61,62 Even the crystal structures of 
a human telomeric quadruplex containing K+ ions show all strands parallel with propeller 
loops 47 and this structure may be the favourite one in cellular environments. 
In parallel with the developing interest in telomeric G4s in the 1990s, potential 
quadruplex structures were identified in other positions of the genome, such as gene 
promoters of human oncogenes and cancer-associated genes, where quadruplex 
formation may have a role in transcription regulation.63 G-rich sequences have found 
generally in nuclease hypersensitive/transcriptional activation sites within or upstream 
the promoter regions of genes including c-MYC,64,65BCL-2,66,67c-KIT,68,69 HIF,70,71RET72 and 
VEGF.73 Promoter G4s have showed wide sequence variability. 2D-NMR studies have 
revealed that the majority of the adopted quadruplexes in promoter regions have the 
parallel topology, typical of those sequences having at least one short (one or two single-
nucleotide) propeller loop (Fig. 2.2 b). 
 
Figure 2.2. a) View of a (3 + 1) hybrid human telomeric quadruplex, (PDB code 2HY9)determined by 2D-NMR.45,59b) 
View of the parallel quadruplex formed from a sequence in the human VEGF promoter (PDB code 2M27), determined 
by 2D-NMR.45,73 
 
 
It must also be said that G-quadruplex folding is very likely to occur within the single 
stranded RNA. It has been shown that G-quadruplex formation in the untranslated region 
of the NRAS oncogene results in inhibition of gene translation55 These findings have 
stimulated a growing interest in this field.  
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2.1.2. G-quadruplex structures as targets for anticancer therapy 
 
Targeting G-Quadruplexes In Telomeres  
 
Telomeres are located at each end of chromosomes and their role is to protect them from 
catastrophic events.57 In vertebrates, telomeric DNA comprises tandem repeats of the 
guanine-rich sequence d(TTAGGG), found in the single-strand overhang.74 The 3’ 
telomeric single strand DNA is associated with various proteins, such as telomeric-repeat-
binding factor 1 and 2 (TRF1 and TRF2), which might be involved in loop-back 
structures,75–77 while telomere end is capped by protection of telomeres 1 (Pot1).78 
Telomeric guanine rich sequence is also able to adopt specific G-quadruplexes, which are 
recognised by several proteins, suggesting a biological role of these DNA secondary 
structures in telomere regulation.79,80   
In normal cells, since DNA polymerase is not able to fully replicate the lagging DNA strand, 
telomere length progressively decrease after each cell cycle and this phenomenon is 
known as ‘end-replication effect’. Once the telomere shortening reaches the ‘Hayflick 
limit’, cells entered a phase of replicative senescence.81 In striking contrast, in cancer cells 
telomere length remains constant and this is dependent on the activity of a RNA-
dependent DNA polymerase, known as telomerase.82 The telomerase catalytic subunit 
(hTERT in humans) active site provides to the assembly of nascent telomeric DNA onto 
the 3′ telomeric DNA end. The elongation process occurs by hybridizing the terminal 3′ 
end of the telomere on a complementary RNA template which is part of a large 451-
nucleotide RNA domain (hTR in humans) of the enzyme.83 
Telomerase catalyses telomere extension, leading to cell immortalization: it is 
overexpressed in around 85% of all human cancers and it is involved in tumorigenesis.84,85 
Inhibition of telomerase would result in effective anticancer effects, however direct 
telomerase inhibition correlates with an extended time-lag before telomere lenght 
reaches the critically shortening, which would lead to senescence and apoptosis.86 
An alternative strategy is the indirect inhibition of telomerase, by targeting telomeric G-
quadruplex with small molecules (Fig. 2.3).87 The enzymatic activity of hTERT can be 
inhibited by the 3′ telomeric single-strand folding into a quadruplex structure, because 
telomerase can’t attach to the single strand DNA. Quadruplex formation in the telomeric 
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DNA effectively inhibit the hybridization between the DNA and the RNA template.88 G4s 
stabilizing small molecules can inhibit the ability of the telomerase enzyme complex to 
maintain the integrity of telomeres in cancer cells and this results in rapid DNA damage 
and consequent cell death, while direct telomerase enzymatic inhibitors induce these 
effects after the full extent of telomeric DNA shortening. ‘Telomere targeting’ is used to 
describe the behavior of the well-studied G4-binding compounds RHPS489 and BRACO-
19,90 which target the single-stranded telomeric DNA overhang in tumor cells, leading to a 
rapid uncapping of hPOT1 and telomerase, thus resulting in telomerase inhibition and 
activation of DNA damage responses and cellular apoptosis.91 
 
 
 
Fig.2.3. Scheme of the cellular consequences of inducing telomeric quadruplex formation by a small-molecule.92  
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Targeting G-quadruplexes in oncogene promoters 
 
G-quadruplex forming sequences have been found upstream and close to the 
transcription start site of several genes. These findings supported the hypothesis that 
quadruplexes play an important role in gene regulation (Fig. 2.4).93  
G-quadruplex stabilization at this level by small molecules may alter the transcription of 
several oncogenes of relevance in human cancer, such as c-MYC and c-KIT, thus exerting 
anticancer effects.94  
 
 
Figure 2.4. Model for transcription modulation via formation of a quadruplex in a promoter region.93 
 
The c-MYC oncogene, which encodes a transcription factor involved in cell cycle 
progression, apoptosis and cellular transformation and whose expression is deregulated 
in up to 80% of all solid tumours, represents a potential therapeutic target.95,96  
However, it has been considered undruggable at the protein levels, owing to its short 
half-life.97 To overcome this issue, targeting c-MYC at the gene level may represent a 
promising anticancer approach. The pivotal publication in this field reported that the 
transcription of c-MYC oncogene could be repressed by targeting a G-quadruplex in the 
nuclease hypersensitive element (NHE III) in the promoter regions of c-MYC with a small 
molecule (TMPyP4).98 It was demonstrated that also quindolines and actinomycin D affect 
c-MYC transcription, by stabilizing G-quadruplex.99,100 
The proto-oncogene c-KIT encodes a receptor tyrosine kinase that plays a key role in cell 
proliferation, differentiation and survival.101 Gastrointestinal stromal tumours (GIST) 
pathogenesis has been correlated to the constitutive activation of c-KIT.102 Kinase 
inhibitors imatinib (Gleevec; Novartis) and sunitinib (Sutent; Pfizer) target c-KIT at the 
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protein level. However drug resistance is an emerging issue and a novel approach may be 
targeting the G-quadruplex in promoter regions of this oncogene.103 
Two G-quadruplex-forming sequence motifs were identified in the core promoter of the 
human c-KIT oncogene and they are known as c-kit168 and c-kit2.104  
It was shown that an isoalloxazine small-molecule binds both c-kit G-quadruplexes and 
reduce the levels of c-KIT transcription in a cell line.105   
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2.1.3. G-quadruplex binders 
 
As stated in the above paragraphs, G4s are considered interesting targets, at both 
telomeric and oncogene levels, and their stabilization by small molecules represents a 
promising strategy for therapeutic intervention with focus on cancer. All quadruplex 
structures are very different from duplex nucleic acids, therefore they may be potentially 
recognized by molecules in a specific manner. 
The growing interest in G-quadruplex structures as targets led to the identification of over 
1000 G4-ligands, representing a wide range of chemotypes.32,45,106  
Some of G4 ligands have been identified in order to target the grooves or the loops of G4 
structures, although the majority of them primarily stack on the external G-tetrads of G4s 
(Fig. 2.5). 107 
 
Figure 2.5. Examples of the binding modes of ligand to G-quadruplex.107 
 
 
The structural features that facilitate the stacking binding mode are: (i) the presence of an 
extended planar aromatic scaffold that can efficiently stack on terminal G-tetrads through 
π−π stacking, (ii) an electron-deficient aromatic core that can enhance stacking 
interactions on G-tetrads via cation−π interaction, and (iii) the presence of cationic side-
chains which can interact with the grooves and loops of G4 and with the negatively 
charged phosphate backbone. 
The G4 ligands can be classified in two main structural groups: i) polycyclic and ii) 
cyclic/acyclic non-polycyclic ligands.32 
  
27 
 
 
i) Polycyclic G4 ligands  
The first identified G-quadruplex interactive ligand able to inhibit telomerase in vitro was 
the amido-anthraquinone derivative reported in Fig 2.6.87 Owing to its structure, planarity 
started to be perceived as an essential feature for effective G4 binding.  
 
 
Figure 2.6. Anthraquinone derivative.87 
 
The acridine-based compounds such as RHPS4108 and BRACO-1990,109 (Fig.2.7) are potent 
G4 stabilizers which inhibit telomerase activity. They have shown low micromolar in vitro 
cell growth inhibition activities and also in vivo antitumor activity against xenograft 
models.  
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Figure 2.7. Acridine derivatives. 
 
X-ray crystallographic data are available on a human telomeric G4 complex with BRACO-
19 and show the BRACO-19 molecule bound to one end of the G4, making π–π interaction 
with the terminal G-quartet and with side chains held within loops.110 This external 
binding mode is different from the internal binding of intercalating agents that interact 
with duplex nucleic acids and this difference may be relevant in terms of G4 selectivity 
over duplex DNA.  
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A number of chemotypes have been identified from natural products. Notable examples 
are the plant alkaloid berberine (Fig. 2.8), which binds human telomeric DNA with end-
stacking features analogous to BRACO-19.111  
 
Figure 2.8. Example of G-quadruplex-interactive natural molecule. 
 
The expansion of the aromatic planar surface of berberine led to the quinolinobenzo-
[5,6]-dihydroisoquindolium scaffold, bearing an additional pyridine ring and amino group 
(Fig. 2.9) with respect to the natural alkaloid, thus increasing the selectivity for c-myc G-
quadruplex. The derivative reported in Fig. 2.9 was able to induce the down-regulation of 
c-MYC transcription in cancer cells.112  
 
Figure 2.9. Quinolinobenzo-[5,6]-dihydroisoquindolium derivative. 
 
Tetra-substituted naphthalene diimide derivatives (NDs) with positively charged termini 
are a distinct group of potent G4-binding agents. The pharmacological properties of ND 
compounds were improved by replacing two N-methyl-piperazine groups by less basic 
morpholine groups, without affecting quadruplex interaction. The lead compound 
reported in Fig. 2.10 has shown low nanomolar potency against several cancer cell 
lines.113  
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Figure 2.10. Naphthalene diimide derivative. 
 
For c-myc promoter quadruplexes only 2D-NMR structures have been determined. A 
noteworthy example is the monosubstituted quindoline 2:1 complex, which shows the 
ligand bound to each terminal G-quartet face, with additional stabilization by interaction 
with 5′ and 3′ flanking nucleotides (Fig. 2.11).114 
 
Figure 2.11. View of the 2:1 complex between a monosubstituted quindoline compound  and a c-myc promoter 
complex, determined by 2D-NMR (PDB code 2L7V).114  
 
The synthetic compound quarfloxin, (CX-3543) (Fig. 2.12) based on a pentacyclic 
benzo[b]pyrido[3,2,1-kl]phenoxazine (i.e., a fluoroquinolone core), is the sole G4-binding 
small molecule that has progressed to clinical trials. It’s believed that quarfloxin binds 
multiple G4s in ribosomal DNA, affecting interaction with the protein nucleolin, leading to 
ribosome synthesis inhibition and apoptosis.33 
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Figure 2.12. Chemical structure of quarfloxin. 
 
ii) Cyclic/acyclic non-polycyclic G4 ligands  
The macrocycle telomestatin (Fig. 2.13) comprising hepta-oxazole and a single chiral 
dihydro-thiazole group was isolated from Streptomyces anulatus.115 Telomestatin showed 
high G4 affinity and selectivity, stabilizing the anti-parallel form of the human telomeric 
G4.116, and strongly inhibited telomerase function and had significant antitumour activity 
in vitro and in vivo.117 It is atypical G4 stabilizer, as it does not have any protonated side 
chains. 
 
 
Figure 2.13. Chemical structure of telomestatin. 
 
Recent findings showed that pyridostatin (Fig. 2.14), a G4-selective ligand,118 causes DNA 
damage in cells predominantly at the SRC gene, which contains a high number of putative 
G4-forming sequences.119  
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Figure 2.14. Chemical structure of pyridostatin. 
 
 
In many studies reported so far G-quadruplex interactive small molecules have showed 
also biological effects with variable degree of success. However, the development of such 
molecules as anticancer drugs still requires further efforts especially because of the 
selectivity issue. Higher selectivity for G-quadruplex over duplex DNA is required. 
Moreover the selective activity towards a single G-quadruplex structure needs further 
investigations. Another key problem is that, in traditional medicinal chemistry terms, 
most of the identified molecules are not ideal since they show features which don’t 
match with Lipinski criteria for orally-bioavailable drug-like compounds. Indeed, large 
planar molecules are not normally considered to be ideal pharmacophores, for their 
hydrophobicility. Small saturated rings such as pyrrolidine, piperidine or piperazine are 
commonly used as well as tertiary amines such as -NMe2 or -NEt2 to enhance aqueous 
solubility and G4 affinity, while the number of side-chains can be important for enhancing 
selectivity between different G4s.  
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2.2. Aim of the project 
Among G-quadruplex binders reported in literature, compound 1 (Fig. 2.15), which 
emerged from a screening of diimidazo[1,2-a:1,2-c]pyrimidine derivatives developed by 
my research group, was identified as a potent stabilizer of several G-quadruplexes over 
duplex DNA.41 This compound doesn’t show conventional alkylamino substituents, with 
respect to other G-quadruplex ligands, but instead has two structurally more rigid 
guanylhydrazone groups. However compound 1 showed a very modest antiproliferative 
activity probably because it is not readily taken up into most cells.  
 
Figure 2.15. Bis-guanylhydrazone derivative of diimidazo[1,2-a:1,2-c]pyrimidine. 
 
A library of analogues of 1 was designed and synthesized to shed light on the structural 
requirements for the effective binding to G4s (Fig. 2.16). The effects of structural changes 
of 1 involving in particular the guanyl chains, the substituents at positions 2 and 8 and the 
core itself were investigated employing both human telomeric and oncogene promoter 
G4s with different topologies as targets. 
 
Figure 2.16. Library of designed hydrazone derivatives.  
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The guanyl chains have been replaced with an imidazoline moiety (compounds 2 and 3) or 
hydrazinopyridyl group (compound 4). The guanyl chains have been maintained, while 
phenyl rings at positions 2 and 8 have been replaced with the bioisostere thiophene in 
compound 5. The tricyclic core has been substituted with different systems: the 
pyrroloindole nucleus (compound 6), a chloroindole moiety (compounds 7, 8). The planar 
bisindole system of indigo was introduced, and then functionalized with iminoguanyl or  
hydrazinopyridyl groups in order to obtain compounds 9 and 10.  
The binding properties of the synthesized compounds to human telomeric and oncogene 
promoter G4s with different topologies as targets were investigated in vitro. The 
compounds that show the most interesting stabilizing effects were further studied by 
applying biophysical methodologies. Finally biological studies in cancer cell lines were 
performed in order to study the association between the G4 stability effect in living cells 
and potential anticancer activity of selected hydrazone derivatives. 
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2.3. Results and discussion 
2.3.1. Chemistry 
 
The hydrazones 2−5 (Schemes 2.1 and 2.2) and 6−10 (Schemes 2.3−2.5) were synthesized 
by reaction between an aldehyde or a ketone and the appropriate hydrazine: 
aminoguanidine hydrochloride, 2-hydrazino-2-imidazoline hydrobromide, or 2-hydrazino-
2-pyridine hydrochloride.120  
 
 
 
Scheme 2.1. 
 
 
The diimidazopyrimidine core bearing two phenyl rings in positions 2 and 8 (compound 
13a) was obtained in two steps starting from 2,4-diaminopyrimidine 11 in presence of 2-
bromoacetophenone. The corresponding bis-aldehyde (compound 14a) was synthesized 
through a Vilsmeier reaction in presence of POCl3 and DMF by means of a procedure 
described in literature (Scheme 2.1).121 
The next step was the reaction between 2-hydrazino-2-imidazoline and aldehyde 14a and 
two products were isolated from the reaction mixture. Indeed, in addition to the bis 
hydrazone 2, it was obtained also the mono hydrazone derivative 3 (Scheme 2.1).  
 
 
NMR experiments were performed to clarify which aldehyde group reacted to give the 
corresponding mono hydrazone
formyl group at 9 position was more reactive than that one at position 3. Indeed t
irradiation of the CHO at 10.09 ppm provided a NOE correlation
pyrimidine proton at 9.12 ppm 
irradiated, no NOE effect at the
suggest that the unreacted 
 
 
 
 
Figure 2.17. NOE experiments on compound 
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On the other hand, when bis-aldehyde 14a was allowed to react with 2-hydrazino-2-
pyridine, only the corresponding bys-hydrazone derivative 4 was obtained (Scheme 2.1).  
All the hydrazones have been obtained as hydrochlorides or hydrobromides, in which, as 
previously reported,122 the side chains are protonated and the positive charge is 
delocalized on the nitrogens of the guanyl or of the imidazoline groups.  
Indeed, 1H NMR spectra of guanylhydrazone derivatives display at about 8 ppm a broad 
signal integrating to eight protons and exchanging after D2O addition, therefore the two 
guanyl groups are protonated. Also the 1H NMR spectrum of compound 3 (Fig. 2.18) show 
a broad signal at about 8.5 ppm integrating to two protons due to the protonated 
imidazoline nitrogens. Interestingly, owing to protonation and charge delocalization, the 
imidazoline ring become symmetric, therefore the protons of the two -CH2 are chemically 
equivalent and give only one 1H NMR signal: a singlet at 3.73 ppm that integrates to four 
protons. 
 
 
 
 
Figure 2.18. 1H spectrum of compound 3. 
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Compound 13b (Scheme 2.2) was obtained in two steps by reacting 2,4-
diaminopyrimidine 11 with 2-bromo-1-(thiophen-3-yl)ethan-1-one. Even when 11 was 
treated with an excess of 2-bromo-1-(thiophen-3-yl)ethan-1-one in order to obtain 13b 
directly, the intermediate 12b is formed as the hydrobromide and it was necessary to 
prepare the corresponding base before treating it again with 2-bromo-1-(thiophen-3-
yl)ethan-1-one.  
 
Scheme 2.2. 
 
Analogously to compound 12a (Scheme 2.1),123 and as determined by two NOE 
experiments, the first cyclization involved the nitrogen at position 1 and the amino group 
at position 2 and led to the bicyclic compound 12b.  
The first NOE experiment confirmed the spatial closeness of the pyrimidine proton at 
position 6 and the amino group, as suggested by NOE correlation between the doublet at 
6.37 ppm (H-6 pyrimidine) and the signals at 8.36 ppm (the other pyrimidine signal) and 
7.16 ppm (amino group). The second NOE experiment, performed by irradiating on the 
doublet at 8.36 ppm, provided a correlation with the signals at 6.37 ppm (H-6 pyrimidine) 
and 7.74 ppm (imidazole), thus confirming the structure of 12b. 
The second cyclization between 12b and 2-bromo-1-(thiophen-3-yl)ethan-1-occurred with 
lower yield than the first one. 
The aldehyde 14b was obtained by means of the Vilsmeier reaction on compound 13b 
performed under reflux in order to promote bis-formylation. In the last step of the 
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synthetic procedure, aldehyde 14b reacted with aminoguanidine hydrochloride to give 
the corresponding bis-hydrazone 5 (Scheme 2.2). 
The diimidazopyrimidine core of the lead compound 1 was replaced with the 
pyrroloindole nucleus in compound 6 (Scheme 2.3).  
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Scheme 2.3. 
 
Starting from N1,N3-dimethylbenzene-1,3-diamine (15), in presence of chloroacetyl 
chloride, the acylation of the amino groups was achieved and the intermediate thus 
obtained was cyclized by Friedel−CraŌs alkylaƟon with AlCl3.  
The resulting pyrroloindole, compound 16, was then allowed to react under reflux 
conditions with the Vilsmeier reagent, formed in situ to achieve the bis-formylation. The 
obtained compound 17, in presence of aminoguanidine hydrochloride, gave the 
corresponding bis guanylhydrazone 6 in good yield.  
 
  
 
 
A chloroindole moiety was introduced in compounds
simplification. The chloroindole was synthesized following a similar procedure which led 
to the pyrroloindole scaffold (Schemes 
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The planar bisindole system of indigo was introduced as central core in compounds 9 and 
10. In order to avoid intramolecular H bonds, which would make the ketones less 
reactive, it was necessary to functionalize the amino groups of indigo (compound 24) with 
methyl groups in presence of methyl iodide (Scheme 2.5) in order to obtain compound 
25, as reported in literature.124 
 
 
Scheme 2.5. 
 
 
Therefore compound 25 was subsequently used in the reaction with aminoguanidine 
hydrochloride, or 2-hydrazino-2-pyridine hydrochloride to afford compounds 9 and 10 
respectively (Scheme 2.5).  
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2.3.2. Biophysical studies 
 
Circular dichroism and FRET studies120  
 
The synthesized compounds 1–10 were evaluated for their ability to interact and to 
stabilize several G-quadruplex structures with different topology. 
To this aim G4-forming sequences able to form parallel, antiparallel, and hybrid G4 
structures were selected.  
Human telomeric DNA G4s can adopt different topologies depending on the selected 
sequence and experimental conditions.125 
Two human telomeric DNA sequences, namely Tel23 and Tel26, able to form the hybrid-1 
fold and the hybrid-2 fold respectively, were selected for this study. 
However several studies suggest that the parallel G4 fold47 is the prevalent one in the 
cell.126 Therefore, the parallel G4 conformation (namely Tel23-p) was also used in this 
study and it was prepared from Tel23 sample, using high DNA concentration conditions in 
order to promote the parallel topology. 
Moreover the two G4-forming sequences from the nuclease hypersensitive region of the 
c-KIT promoter (c-kit1 and c-kit2) and one from the c-MYC promoter (c-myc) were also 
used. 
Circular dichroism (CD) spectroscopy was used to verify the structures adopted by each G4 
sample. 
Tel23-p, c-kit1, c-kit2, and c-myc displayed a positive band at 264 nm and a negative one 
around 240 nm in the CD spectrum, which are characteristic of parallel-stranded G4 
topologies, according to data reported in literature.127,128 On the other hand, Tel23 and 
Tel26 showed very similar CD spectra having a positive band at 289 with a shoulder at ca. 
268 nm and a weak negative band at around 240 nm. These data are consistent with the 
presence of hybrid structures as major conformations. 
Moreover it was observed, by means additional CD experiments, that in presence of 4 
mol. equiv. of each compound, no significant variations of CD signal of the analyzed G4 
structure were obtained, suggesting an overall preservation of the G4 native topology 
upon the addition of each ligand.  
Also the structure of a duplex DNA (ds12) was also verified by CD spectroscopy. 
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In the presence of K+, the CD spectrum of ds12 was characterized by a positive band at 
around 280 nm and a negative one at 250 nm and even these bands were not modified 
upon ligand addition. 
CD melting experiments were performed in order to evaluate the stabilizing properties of 
the newly synthesized compounds. To this aim, the ligand-induced change in the melting 
temperature (ΔTm) of G4 and duplex structures were measured, using a 4:1 ligand/DNA 
so that all possible G4 binding sites were available. CD-melting curves of DNAs in the 
absence and presence of each ligand were obtained by following the variations of the 
intensities of CD signals at the wavelength of 264, 290, and 280 nm for parallel G4s, 
antiparallel G4s, and duplex, respectively. 
The results of the CD melting experiments are listed in Table 2.1.  
 
Table 2.1. Ligand-induced thermal stabilization of G4 and duplex DNAs measured by CD melting experiments.  
∆Tm (°C)
a 
Compound c-kit1b c-kit2c c-mycc Tel23-pb Tel23b Tel26b ds12b 
1d >15.0 >20.0 >20.0 >20.0 -10.0 -4.5 0.1 
2 1.6 >20.0 >15.0 10.8 -14.0 -8.9 1.3 
3 2.7 9.5 >20.0 9.1 -2.4 -3.0 -0.8 
4 0.4 0.0 -0.2 1.3 -1.0 -1.6 0.9 
5 >15.0 >20.0 >20.0 >20.0 -4.9 -6.5 3.5 
6 >15.0 >15.0 >20.0 >20.0 3.0 1.3 NDe 
7 >15.0 >20.0 >20.0 >20.0 6.0 5.8 NDe 
8 >15.0 >15.0 >20.0 >20.0 5.6 5.1 NDe 
9 0.9 8.2 11.0 7.7 -0.5 0.2 -0.8 
10 1.5 2.0 1.6 4.0 -2.5 -2.0 -0.7 
aTm represents the difference in melting temperature [Tm = Tm(DNA + 4 ligand equiv.) - Tm(DNA)]. The Tm values of DNAs alone are: c-kit1 = 69.8 
 0.5 °C; c-kit2 = 62.5  0.5 °C; c-myc = 72.9  0.5 °C; Tel23-p = 68.5  0.5 °C; Tel23 = 65.2  0.5 °C; Tel26 = 59.5  0.5 °C; ds12 = 71.3  0.5 
°C. All experiments were duplicated and the values reported are average of two measurements. b100 mM KCl buffer. c20 mM KCl 
buffer. dLead compound. eThese compounds significantly increase the thermal stability of ds12 however Tm values cannot be 
accurately determined. 
 
On the basis of the obtained data, compounds may be divided in three groups: (i) 
compounds that exhibit poor G4-stabilizing properties towards any G4 (ΔTm < 5 °C) 
(compounds 4 and 10); (ii) compounds showing medium G4-stabilizing effect (ΔTm = 5−15 
°C) (compound 9); (iii) potent G4 stabilizers (ΔTm > 15 °C) (compounds 2, 3, 5−8). Most of 
the compounds investigated showed high selectivity for G4 over duplex DNA, analogously 
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to lead compound 1. However, compounds 6, 7, and 8, having a different core from 
compound 1, were the only ligands which significantly increase duplex stability and 
therefore were not considered to be selective. Interestingly, compounds 2, 3, and 5 
preferentially stabilized parallel G4s over antiparallel ones. In particular, compound 3 
induced a marked stabilization of c-myc G4 (ΔTm > 20 °C). 
CD melting studies were further performed on the most selective compounds 2, 3, and 5 
to investigate the effect of increasing concentrations of the ligand on the stability of both 
c-kit2 and c-myc G4s (Figure 2.21).  
 
 
 
 
Figure 2.21. CD melting experiments of c-kit2 and c-myc G4s with increasing amounts of compounds 2, 3, and 5. 
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Three different [ligand]/[DNA] ratio were examined (1:1, 2:1, and 4:1). In the case of c-
kit2, a dose dependent increase of thermal stability was observed for all three 
compounds. In particular, compounds 2 and 5 increased the Tm of the G4 with every 
addition of ligand, while 3, which had shown a modest increase in c-kit2 stability, did not 
induce any further increase of Tm beyond the 2:1 [ligand]/[DNA] ratio. In the case of c-
myc G4, a considerable increase of the melting temperature was registered with 
compound 3 and the stabilization effect ceased at a 2:1 ratio. On the other hand, 
concentration dependency was observed for 2 (although slight compared to c-kit2), while 
the high G4-stabilizing effect of 5 on c-myc did not permit to evaluate any dose-
dependent effects.  
Overall, these results indicate that six out of nine synthesized ligands are potent G4 
stabilizers. The diimidazo[1,2-a:1,2-c]pyrimidine derivatives having a positive charge on 
the side chain(s) in the used experimental conditions (i.e., 2, 3, and 5) showed high 
affinity towards some of the investigated G4 structures. Conversely, compound 4, whose 
side chain protonation is less favorable at pH 7.0, showed generally poor G4-stabilizing 
properties. Their duplex-binding activity is negligible. Among compounds with a different 
core, the positively charged ones (6, 7, and 8) showed affinity for some of the G4s 
investigated as well as for duplex DNA. Compounds 9 and 10, whose side chain 
protonation is less likely to occur at pH 7.0, showed medium to low G4-stabilizing 
properties and negligible effects on duplex. These results indicate that the overall charge 
of compounds is necessary but not sufficient to ensure potent and selective interaction 
with a specific DNA structure. In addition, CD melting data suggest that two molecules of 
3 could bind and stabilize the G4 target.  
The G4 stabilizing properties of compounds were also evaluated by FRET 
methodology.129To fully compare the results of CD melting experiments obtained for 
compounds 2, 3, and 5, FRET melting experiments were performed on these ligands 
under the same buffer conditions used for CD, using as targets the labeled G4-forming 
oligonucleotides from the c-KIT (Fckit2T) and c-MYC (FcmycT) promoter regions and the 
telomeric G4-forming sequence annealed at high concentration to promote the parallel 
conformation (F21T-p). The results of FRET melting experiments, shown in Table 2.2, are 
in agreement with those obtained from CD melting studies.  
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Table 2.2. Ligand-induced thermal stabilization of labeled G4-formingsequences evaluated by FRET melting analyses 
     ∆Tm (°C)a 
Compound Fckit2Tb FcmycTb F21T-pc 
2 >20.0 >15.0 >15.0 
3 ≈15.0 >20.0 7.0 
5 >20.0 >20.0 >20.0 
 
aTm represents the difference in melting temperature [Tm = Tm(G4 + 4 ligand equiv.) - Tm(G4)]. Tm values of G4s alone: Fckit2T = 66.3  1.0 °C; 
FcmycT = 68.6  1.0 °C; F21T-p = 67.1  1.0 °C. All experiments were duplicated and the values reported are average of two 
measurements. b20 mM KCl buffer. c100 mM KCl buffer. 
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Nuclear magnetic resonance studies120  
 
CD melting studies and FRET melting studies revealed that compound 3 is a potent and 
specific stabilizer of c-myc G4 and therefore its binding mode was futher studied in detail 
by means of NMR spectroscopy. 
The well-characterized modified sequence (Myc22) containing two G-to-T mutations at 
position 14 and 23 was used for the NMR titration experiments.  
According to the literature, under the experimental conditions used, the Myc22 DNA 
sequence forms a single G4 conformation characterized by 12 well-resolved imino 
protons peaks, corresponding to the 12 guanines involved in the three G-tetrad planes.130 
Upon addition of compound 3 to the Myc22 solution, both imino and aromatic protons 
became broad even at higher drug equivalence, indicating a dynamic binding process of 3 
to Myc22. The titration was virtually complete at a ligand/DNA ratio of 2:1 (Fig. 2.22).  
 
Figure 2.22. Imino and aromatic proton regions of c-MYC promoter G4 (Myc22) in 25 mM phosphate, 70 mM KCl 
solution (pH 7.0). 
 
Major chemical shift changes were observed for the imino protons belonging the 5’ G-
tetrad (G7−G11−G16−G20) as well as for G9 of the 3’ G-tetrad (G9−G13−G18−G22). This 
may be explained by the structural features associated with the 3’- and 5’-faces as well as 
the flanking sequences. Indeed the 5’-side is more accessible for ligand stacking and the 
only 5’-flanking residue particularly affected by the binding turned out to be the T4, as 
shown by the corresponding aromatic proton shift. By contrast, the 3’-face is less 
accessible. A25 from this side folds back to form a base pair with T23 to cover the 
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external G-tetrad, while A24 stays above the T23:A25 base pair. However, these latter 
flanking residues are not able to completely prevent the binding. Upon addition of 3, the 
aromatic protons of T23, A24, and A25 were strongly perturbed, suggesting that the 
ligand can be positioned between the four guanines of the 3’-tetrad and the 3’-flanking 
bases. The stability of the 3’-end bound ligand complex with Myc22 could be related to 
the possibility of specific H-bond interactions between the imidazole group of 3 and the 
3’-flanking bases. The binding behavior of 3 to the c-kit2 G4 was also evaluated. The 
modified sequence c-kit2T12/T21 (in which G12 and G21 are replaced by two T residues), 
which is known to fold into a monomeric parallel G4 structure with well-resolved imino 
proton signals131,132 was used for this study. Interestingly, the imino signals belonging to 
the G-tetrad on the 5’-side (G2, G6, G14, and G18) were equally affected with respect to 
those belonging to the 3’-terminal G-tetrad, as well as the aromatic protons of C1 and 
A13 on the 5’-face and those of C9 and T21 on the 3’-face (Fig. 2.23).  
 
Figure 2.23. Imino and aromatic proton regions of c-KIT promoter G4 (c-kit2T12/T21) in 5 mM phosphate, 20 mM KCl 
solution (pH 6.8) titrated with compound 3. 
 
These results clearly suggest an involvement of both external G-tetrads in binding, 
despite the potential pairing between residues C1 and A13 on the 5’- side.131 It may be 
hypothesized that 3 is able to interact with both the 5’ and 3’ G-tetrads, possibly by 
displacing the C1 and A13 base pairing at the former. 
Overall, these findings suggest that compound 3 binds to the 5’- and 3’- terminal G-
tetrads of both Myc22 and c-kit2T12/T21 G4s. However, some differences in the binding to 
the two G4s have been observed and they may due to specific interactions formed 
between 3 and Myc22.   
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2.3.3. Molecular docking120 
 
To provide a molecular basis for the G4 binding of 3, molecular docking calculations were 
also performed. The ligand was docked to the three-dimensional structures of c-kit2 and 
c-myc G4s determined by solution state NMR spectroscopy.132,114  
2:1 (ligand/DNA) complex models were built with the G4 targets, taking into account the 
binding stoichiometry suggested by previously described NMR studies. Both 5’- and 3’- 
terminal G-tetrads were considered as potential binding sites for the ligand. The tricyclic 
diimidazo[1,2-a:1,2-c]pyrimidine moiety is stacked onto the planes at a 3.4 Å separation 
at both 5’- and 3’-faces and overlaps part of two guanine bases (G11 and G16 at the 5’ G-
tetrad; G9 and G13 at the 3’ G-tetrad), making extensive π-stacking interactions in the 
low energy binding pose on c-Myc G4 showed in Fig. 2.24.  
 
 
Figure 2.24. Predicted binding poses upon docking of compound 3 onto the (A) c-myc and (B) c-kit2 G4s.  
 
In both cases, one of the two attached phenyl rings overlap part of a guanine of the 
tetrad, contributing to the stabilization, while the other one is twisted out of the 
diimidazo[1,2-a:1,2-c]pyrimidine plane. The 2-hydrazino-2-imidazoline groups of the two 
ligand molecules make close hydrogen bonds with the oxygen atoms of the backbone 
phosphate groups of the G4. It is interesting to observe that the formyl group of 3 is, in 
both cases, hydrogen bonded to the first flanking base (A6 and T23 at 5’- and 3’-end, 
respectively) that stacks over the G-tetrad, thus forming a plane capping the 5’ and 3’ 
external G-tetrads of the c-myc G4. 
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In the case of c-kit2 G4, different binding poses were observed for the ligand on the two 
external G-tetrad surfaces (Fig. 2.24). Indeed, the molecular model of 3 bound to the c-
kit2 G4 shows that at the 3’- end, the planar aromatic scaffold of the ligand makes π-
stacking interactions with the 3’G-tetrad, while the 2-hydrazino-2-imidazoline group is 
positioned to participate in a hydrogen bond with a phosphate group. However, by 
contrast with the c-myc G4, compound 3 does not form any additional interaction to 
further stabilize the complex. On the other hand, the docking calculations at the 5’-face of 
the c-kit2 G4 structure reveal that to make hydrogen-bonding/electrostatic contacts 
between the charged 2-hydrazino-2-imidazoline group and the backbone phosphate 
groups of the G4, the side chain of compound 3 needs to be located in the deep groove 
formed by the long loop 2 of the G4. As a consequence, the diimidazo[1,2- a:1,2-
c]pyrimidine core of 3 results in not being parallel to the plane of the terminal G-tetrad. 
This is probably due to the 5’-3’ strand polarity generated by the propeller loop topology 
of this G4, which does not expose the phosphodiester backbone on this side, thus making 
only the 3’-end more favorable to interact with ligands with positively charged side 
chains. 
Overall, the docking results reveal that 3 has the appropriate shape and electronic 
structure to form specific interactions. Interestingly, the binding of 3 could involve the 
first flanking bases to form a plane covering the external G-tetrads and contributing 
greatly to the G4 stabilization. This could also explain the selectivity of 3 in increasing the 
thermal stability of the c-myc G4. 
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2.3.4. Biological Studies120 
 
The most selective G4-interactive agent 3 was studied also at cellular level in comparison 
with compound 1. Compound 14a was used as a negative control because it is unable to 
bind G4s in vitro.41  
First, a MTT assay was performed in order to evaluate the cell killing activity of the three 
selected molecules in human osteosarcoma U2OS and colon cancer HCT116 cell lines. 
HCT116 cells were more sensitive than U2OS cells to the tested compounds, however, 
both cell lines were more sensitive to compound 3 than other agents (Table 2.3).  
 
Table 2. 3. Cytotoxic activity of selected hydrazone derivatives in human U2OS and HCT116 cells.  
 
IC50 (µM) 1 hour 
 
IC50 (µM) 24 hours 
Compound U2OS HCT116 
 
U2OS HCT116 
1 101.0 ± 1.63 35.07 ± 1.06 
 
15.97 ± 1.41 5.12 ± 1.05 
3 5.73± 1.48 4.18 ± 1.07 
 
0.845± 0.001 0.407 ± 0.106 
14a 45.23 ± 2.05 16.79 ± 1.06   9.16 ±1.44 4.06 ± 1.07 
The concentrations killing 50% of cells (IC50) are means ± SE of two independent experiments performed in 
triplicates. 
 
In particular, compound 3 showed high cell killing activity in U2OS cells after 24 h of 
treatment (IC50 = 0.845 μM). In addition, 3 was 20- and 12-fold more cytotoxic than 
compounds 1 (IC50 = 15.97 μM) and 14a (IC50 = 9.16 μM), respectively. Similarly, 3 was 
more cytotoxic than compounds 1 and 14a after 1 h of cell treatment (Table 2.3). The 
sensitivity pattern was very similar in HCT116 cells, with compound 3 showing highest cell 
killing activity as compared with compounds 1 and 14a both after 24 and 1 h of treatment 
(Table 2.3). These results showed that compound 3 is more cytotoxic than the other 
tested compounds, in the two used cell lines. 
Moreover, immunofluorescence microscopy was used to visualize nuclear G4 structures in 
human U2OS cells and to evaluate the G4 stabilizing properties of 3 and 1 in living cells. 
To this aim the BG4 antibody, a known specific antibody against G4s, was employed.133 
U2OS cells were treated for 24 h with compound concentrations very close to the 
calculated IC50 values.  
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BG4 showed nuclear staining in untreated cells indicating that G4 structures were present 
at discrete chromatin sites in the nucleus (Fig. 2.25). Fluorescence patterns were similar in 
cells treated with the three derivatives. However, the compound effects were very 
different because compounds 3 and 1, but not 14a, markedly increased the number, size, 
and fluorescence intensity of nuclear spots, thus indicating that they could stabilize G4 
structures in the nucleus of living cells.  
 
 
Figure 2.25. Immunofluorescence showing BG4 foci (green) in human osteosarcoma U2OS cell nuclei (blue). Cells were 
treated with G4 ligands for 24 h and then fixed. G4s and DNA were stained with BG4 antibody and DAPI, respectively.  
 
 
Measurements of the total fluorescence signal per cell for each sample indicated that 3 
was the most potent, indeed an increase of G4 signal was detected even at 0.2 μM (a 
dose 4-fold lower than IC50), and further increased at 1 μM, of 3. Compound 1 was able to 
increase the nuclear G4 signal at 10 μM at comparable levels as 3 at 0.2 μM. In contrast, 
14a did not show any increase in fluorescence intensity at the tested concentrations (Fig. 
2.26). 
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Figure 2.26. Box Plot analysis of G4 signal in the nucleus of control and treated cells. At least two experiments were 
considered, and 150 nuclei were counted per sample. Statistical significance was determined with the t test, and * 
indicates a p value less than 10−32.  
 
These data demonstrate that hydrazone derivatives can stabilize G4s in human cancer 
cells and that 3 is the most potent agent among the studied derivatives. Further 
investigations at the cellular level are needed to confirm the correlation between G4 
stabilization and biological activity of these hydrazone derivatives. 
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2.4.  Conclusions 
A series of hydrazone derivatives (2-10) of the lead compound 1 was designed and 
synthesized. CD assays showed that six out of nine compounds are potent G4 stabilizers 
that retain the pre-existing architecture of the target G4s upon interaction. Compounds 
having a different core (6, 7, 8) from that of compound 1 are not selective for G4s. 
Compounds 2, 3 and 5 (Fig. 2.27) displayed a marked preference for binding to parallel 
G4s over duplex and antiparallel G4s.  
 Figure 2.27 
 
The monohydrazone 3 was found to be the most selective of the series. The reduction of 
positively charged side chains number resulted in enhanced selectivity of this derivative 
towards c-Myc G4. NMR experiments suggested an end-stacking binding mode at the 
terminal G-tetrads of the G4 and a 2:1 drug/DNA binding stoichiometry.  
Molecular docking results revealed that 3 has the appropriate structure to stack on the 
planar G-tetrad surfaces of c-myc G4 with the tricyclic diimidazo[1,2-a:1,2-c]pyrimidine 
core and, the same time, to make (i) close hydrogen-bonding/electrostatic contact 
between the charged 2-hydrazino-2-imidazoline group and the oxygen atoms of the 
backbone phosphate of G4, and (ii) a hydrogen bond interaction between the formyl 
group at position 3 and the hydrogen-bond donor groups of the first flanking base that 
stacks on the G-tetrad.  
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In accordance with the in vitro assays, biological experiments demonstrated that 
hydrazone derivatives can effectively trap G4 structures in the nuclei of cells. Derivative 3 
is more effective than the lead compound 1 in inhibiting human U2OS and HCT116 cancer 
cell growth, as well as in stabilizing G4s in osteosarcoma cells. 
The reported results indicate that the diimidazo[1,2-a:1,2-c]pyrimidine molecular scaffold 
should be actually considered for the development of highly-selective drug-like G4 
ligands. Further structural modifications may be performed to explore selectivity for a 
single G-quadruplex  structure and also to improve biological activity.   
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CHAPTER 3 
3. NGR tumor-homing peptides: structural 
considerations for effective APN targeting 
3.1. Background 
3.1.1. Exploring tumor vessels “zip codes”: identification of NGR tumor 
homing peptides  
 
The angiogenesis process, consisting in the formation of new blood vessels from the 
existing vasculature, physiologically occurs during embryogenesis and in the adult during 
female reproductive cycle and wound healing.18,134 Folkman in 1971 was the pioneer of 
the hypothesis that tumor growth and metastasis strictly depend on 
angiogenesis,135therefore marking the beginning of an intensive research in this field. 
Nowadays angiogenesis is considered as a hallmark of cancer.8 Tumors, defined as 
“wounds that never heal”,136 have lost the balances between positive and negative 
regulators of angiogenesis and, as a consequence, the ‘angiogenic switch’ is turned on 
and tumor vessels constantly grow.137  
The formed tumor vasculature appears quite different from the normal counterpart: it 
presents fragility, chaotic architecture, high permeability.138 Moreover tumor vessels 
express specific “zip codes”, surface proteins that are not expressed or are expressed at 
much lower levels in normal vessels.36,139  
Indeed elevated expression levels of receptors for VEGF,140 integrins such as the αvβ3, 
αvβ5 and α5β1,141 peptidases/proteases such as aminopeptidase N (APN/CD13),142 have 
been found on the surface of endothelial cells within tumor vessels. These proteins are 
considered markers of angiogenesis and are also functionally important in the angiogenic 
process.143–145 
Exploiting the differences in vascular ‘‘ZIP codes’’ between normal and tumour 
endothelial cells may be the right approach to develop novel anticancer strategies, such 
as neovasculature-targeted drug delivery systems.146 
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In vivo phage display is considered the most effective technology to probe tumor 
vasculature. It is a high-throughput technique that may be used in both vascular mapping 
and in the identification of ligands that specifically target a particular vascular bed.147 A 
screening of random peptide libraries displayed on phage injected into tumor-bearing 
mice led to the identification of tumor-homing peptides (THPs), able to target selectively 
tumor vasculature of a mouse model.  
Among various peptides identified by Pasqualini et al., the peptide motif containing the 
sequence Arg-Gly-Asp (RGD) (Fig. 3.1), is able to recognize the αvβ3  and αvβ5 integrins, 
which are up-regulated in tumor endothelial cells.37 
 
 
Figure 3.1 
 
In a following publication, the same researchers described that a phage carrying the 
peptide CNGRCVSGCAGRC, containing the sequence Asn-Gly-Arg (NGR) (Fig. 3.1), which 
had been identified as a cell adhesion motif,148,149 accumulated into tumor angiogenic 
vessels within human breast carcinoma xenografts. Furthermore the NGR peptide showed 
higher selectivity toward tumor cells than the RGD peptide.38 A subsequent study 
revealed that the receptor for NGR peptide is aminopeptidase N, which is overexpressed 
in angiogenic blood vessels.142  
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3.1.2. Aminopeptidase N (APN/CD13) as receptor for NGR tumor-homing 
peptides  
 
APN is a cell-surface membrane spanning protein belonging to the M1 family of 
metalloenzymes, consisting of a large number of zinc-dependent aminopeptidases.150 It is 
expressed in some epithelial cells and immune cells.151 
With respect to other aminopeptidases, APN seems to have multifunctional roles and it 
has indeed defined as a “moonlighting ectoenzyme”.152 APN removes preferentially N-
terminal neutral amino acids, such as alanine, from oligopeptides. By cleaving the N-
terminus aminoacid, APN regulates the metabolism of several peptides (e.g.: angiotensin 
III) involved in important biological processes.153 APN acts also as a receptor for some 
viruses, such as the human coronavirus 229E (HCoV-229E). The viral receptor function 
results in APN internalization.154 In addition, it has been proposed that APN exerts some 
functions as signaling molecule.155  
Several findings revealed that APN is associated with the malignant development and it is 
involved, in particular, in tumor aggressiveness and metastasis. It has been reported that 
APN is overexpressed or its enzymatic activity is altered in skin, ovary, thyroid, lung, 
stomach, colon, kidney, bone and prostate tumors.156 APN has been linked to increased 
migratory capacity of tumor cells, chemochine processing and tumor invasion.157,158 Anti-
APN antibodies block tumor migration, probably because APN has a role in extracellular 
matrix proteins degradation.159 However tumor cells that overexpress enzimatically 
inactive APN also show increase migration and metastasis, therefore APN may influence 
cell motility in a manner that is not dependent on its enzymatic activity.160 Moreover APN 
interacts with cell-surface proteins, playing a role also in cell-cell adhesion.155,161 
Pasqualini and co-workers identified APN as the receptor for NGR containing tumor-
homing peptides. They showed that phage displaying NGR-peptides were able to bind 
specifically immunocaptured APN and APN-transfected cells and this binding was 
inhibited by the cognate soluble peptide; moreover anti-APN antibody inhibited in vivo 
homing of NGR phage into tumors. Furthermore they showed that the only vascular 
structures with detectable APN are tumor blood vessels and other types of vessels 
undergoing angiogenesis. So, it was established that APN is a marker of angiogenesis and 
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it plays also a functional role in tumor angiogenesis. Bestatin, a known APN inhibitor, 
inhibited angiogenesis in vivo and also suppressed tumor growth, showing good 
antitumor activities. In addition antibodies against APN inhibited tumor angiogenesis.142  
In a consequent study it has been proposed that the isoform of aminopeptidase N 
expressed in tumor vessels may be different from that in normal cells, thus explaining the 
selectivity of NGR tumor-homing peptides.162 
According to a recent paper reported in literature by Liu et al., APN interacts with the 
NGR tumor-homing peptide, with a similar recognition mechanism used for interacting 
with the NGR motifs within ECM proteins (Fig. 3.2). This can explain both the enzymatic-
independent tumor cell-motility mediated by APN and the tumor-homing peptide binding 
to APN.163 
These findings have prompted an intensive research in both therapy and diagnosis of 
cancer, in which NGR/APN recognition may be used to develop conjugates between NGR-
peptide and an anticancer drug and/or an imaging agent. 
 
 
Figure. 3.2. Black loops indicate the NGR motif present in tumor-homing peptide connected to an anti-tumor drug and 
in ECM proteins.163  
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3.1.3. NGR peptide-based agents  
In the last decade tumor-homing peptides have emerged as promising carriers for 
targeting anticancer and imaging agents into tumors. Peptide-based delivery of 
compounds has numerous advantages over other delivery systems. Peptides are indeed 
smaller, penetrate more efficiently into tissues and are less immunogenic than 
antibodies.  
Particularly, much attention was focused on tumor-homing peptides containing the NGR 
motif. Due to their ability to bind in a specific manner tumor cells and tumor vasculature 
by interacting with aminopeptidase N, NGR-containing peptides emerged as promising 
tools to deliver therapeutics and imaging probes into tumors. 
As reported by Arap. et al., a pentapeptide containing the NGR sequence flanked by two 
cysteines forming a disulfide bridge (cCNGRC, Fig. 3.3) is sufficient to home into tumors. 
Besides, the cyclic CNGRC peptide homed into tumors more effectively than linear 
peptides. Coupling this peptide with doxorubicin resulted in increased drug efficacy and 
lowered toxicity in mice.38 
 
Figure 3.3. Cyclic CNGRC peptide used as tumor homing carrier. 
 
Considering these advantages, many other studies on conjugates between the cCNGRC 
peptide and small molecules, such as doxorubicin and platinum derivatives (cisplatin and 
carboplatin), have been reported. The cCNGRC peptide has been derivatized either at the 
C-terminus or N-terminus, showing a variable grade of success (Fig. 3.4).164–166  
 
Figure 3.4. Examples of conjugates between cCNGRC peptide and doxorubicin. 
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NGR peptides found another application in the development of doxorubicin (DOX)-
encapsulated liposomes coupled with the NGR motif. In this case improved drug uptake 
by neuroblastoma tumours and enhanced therapeutic efficacy were observed.167 This 
strategy could be effective in tumors characterized by poor vascularisation.  
Also the pro-apoptotic KLAKLAKKLAKLAK peptide was conjugated to the C-terminus of the 
CNGRC peptide and the conjugate selectively killed angiogenic cells.168 
Interestingly, when the c(CNGRC)G peptide was conjugated to the N-terminal domain of 
(h)TNF-α, increased anti-tumor activity and lowered toxicity of this cytokine were 
observed in animal models.169 The cyclic CNGRC coupled to the TNF-α exhibited more 
than 10-fold higher antitumor activities than the corresponding linear derivative.170 The 
c(CNGRC)G-TNF-α construct is able to control tumor growth either alone or in 
combination with chemotherapeutics.171,172 It’s noteworthy that c(CNGRC)G-TNF-α based 
cancer therapy is currently under phase III clinical trials in patients with malignant pleural 
mesothelioma.173  
Furthermore NGR tumor homing peptide represents a powerful tool for tumor imaging 
and to date interesting examples of NGR-based imaging probes have been reported in 
literature.  
The first example of NGR conjugated probes synthesis was reported by Dirksen et al., who 
extended the C-terminus of cCNGRC with a diethylenetriaminepentaacetic acid (DTPA) 
ligand complessed to Gadolinium (III) for MRI and with a fluorescent dye (OG 488) for 
optical imaging, while the N-terminus was maintained in the acetylated form (Fig. 3.5). 
However no imaging studies were reported for this bimodal agent.174  
 
Figure 3.5. The bimodal target-specific contrast agent containing cCNGRC conjugated with 
gadolinium(III)diethylenetriaminepentaacetic acid (Gd(III)DTPA), and Oregon Green 488 (OG488). 
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NGR peptide-based imaging was adapted at the quantum dot (QD)-based imaging 
approach widely adopted in living cells and animal models. When biotin-tagged cNGR was 
attached to streptavidin-coated QDs, the resulting cNGR-QD was highly specific to 
APN/CD13-positive cells.175 
Fluorescent dye Cy 5.5 has been conjugated to NGR peptide and the resulting cNGR-Cy 
5.5 (Fig. 3.6) differentiates APN/CD13-positive fibrosarcoma cells from APN/CD13-
negative MCF-7 cells. cNGR-Cy 5.5 was visualized by fluorescence reflectance imaging not 
only in tumor region but also in kidney and liver, suggesting the rapid renal excretion of 
the conjugate in vivo.176 
 
Figure 3.6. Chemical structure of Cy 5.5-labeled cCNGRC-peptide. 
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3.1.4. Interactions between APN and NGR peptides  
 
Despite the potential of APN-directed tumor-homing strategies, the exact structural 
requirements necessary for APN-NGR recognition and tumor targeting with NGR peptides 
are still not completely clear.  
Chen and co-workers reported the crystal structure of porcine APN (pAPN), which shares 
a high grade of omology with the human one.177 APN is a zinc-dependent ectoenzyme 
consisting in a short N-terminal cytoplasmic domain, a single pass transmembrane 
anchor, a small extracellular stalk and a large C-terminal ectodomain containing the active 
site. The ectodomain of pAPN has a seahorse shape, with 4 domains: head, side, body and 
tail. The zinc-binding active site is located in the body. A negatively charged channel is 
located between the head and the body leading to the zinc-binding active site. The 
substrate poly-alanine (Fig. 3.7 ) has its N-terminal residue anchored to the active site and 
the rest of the peptide bound to the channel. In the APN active site Gln 208, Glu 350, Glu 
406 form three H bonds with the free N-terminal -NH2 group of peptides and other 
ligands, such as the substrate analogue bestatin (Fig. 3.7). These interactions firmly 
anchor the N-terminus of peptides to the active site for catalysis, thus making APN a N-
terminal exo-aminopeptidase. Moreover a hydrophobic interaction is formed between a 
Met349 and the Cβ of the N-terminal amino acid of peptides and this can explain why APN 
prefers alanine at the N-terminus of peptide substrates. APN binds the rest of the 
peptides through hydrogen bonds regardless of peptide sequences.177 
 
 
Fig. 3.7. Structures of APN substrate poly-alanine and APN inhibitor bestatin. 
 
In a subsequent publication the same research group reported the crystal structure of 
porcine APN in complex with the c(CNGRC)G peptide, used as tumor-homing carrier, 
revealing important structural information. X-ray crystallographic data showed 
c(CNGRC)G tumor homing peptide binds to the zinc aminopeptidase active site. The two 
cysteines within c(CNGRC)G form a disulfide bond, thus the NGR region forms a short 
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loop with a sharp turn. The NGR loop makes sequence-specific interactions with the pAPN 
active site through the side chains of Asn and Arg. The presumed scissile peptide bond 
within the c(CNGRC)G backbone is stable against APN hydrolysis (Fig. 3.8).163 
 
 
 
 
 
 
 
 
Figure 3.8. Overall structure of the pAPN- c(CNGRC)G complex.163 
 
 
As mentioned above, the N-terminal amino group of APN natural substrates, such as poly-
alanine and inhibitors, such as bestatin, plays a crucial role in the binding process, forming 
strong interactions with a negatively charged region of the APN catalytic site. X-ray data 
showed that the H2N-Cys-Asn fragment of the cCNGRC peptide overlaps with the N-
terminal H2N-Ala-Ala in APN-bound polyalanine (Fig. 3.9).163 These data suggested that 
the carboxyl terminus on the second cysteine of the tumor-homing peptide plays a less 
important role in the binding to APN. On the contrary the amino function of cCNGRCG 
may be engaged in the binding process. 
 
Figure 3.9. Comparison of the conformations of cCNGRCG in the crystal of the wild type pAPN-cCNGRCG complex and 
the uncleaved poly-alanine peptide in the crystal of mutant pAPN-polyalanine complex (PDB code 4NAQ).163 
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3.2. Aim of the project 
 
Based on the structural data reported in the above section, the amino-terminus of the 
cCNGRC peptide may have an important role in APN binding, therefore the carboxyl-
terminus should be used as functionalization site for the synthesis of cCNGRC-
bioconjugates. Conversely the N-terminus should remain in the free NH2-form.  
Despite a wide range of linear or cyclic NGR peptides has been reported in literature, this 
aspect has never been evaluated. Both then N-terminus165,166,178,179 and C-terminus38,169 
of cCNGRC have been used as anchorage points for bioconjugation, with or without 
protection of the unused terminus.179  
The objectives of this research were i) the investigation of the role of the free N-terminal 
amine function on the binding properties of cCNGRC peptide towards APN and ii) the 
identification of the optimal site for cCNGRC derivatization, in order to provide a rationale 
for the design of APN-targeted cCNGRC constructs.  
To this aim, the basic structure of the cyclic peptide with the free N and C termini (1) and 
a library of cCNGRC peptides bearing differently functionalised N-terminus and C-
terminus was designed and synthesized. The C-terminus was modified by introducing an 
amide group (2), the N-terminus was masked by acetylation (3) the biotin tag was 
introduced on the N-terminus (4) and on the C-terminus in the derivative 5, which was 
further modified by N-terminus acetylation to obtain derivative 6 (Fig 3.10).  
To synthesize the cyclic peptides, solid phase peptide synthesis-based strategies were 
explored. Fmoc-6-aminohexanoic acid and Fmoc-Lys(Dde)OH were used as linkers for N-
terminus and C-terminus functionalization, respectively. 
The effects of the structural modifications on the ability of derivatives 1−6 to inhibit the 
enzymatic activity of APN were investigated. Finally a cCNGRC derivative (7) bearing a 
fluorescent probe (Oregon green 488, OG) on the right functionalization site was 
designed and synthesized for imaging studies in human cancer cells. 
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Figure 3.10. cCNGRC derivatives bearing different moieties on N-terminus and C-terminus. 
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3.3. Results and discussion 
3.3.1. Chemistry 
General procedure for the synthesis of peptides 1—7180 
The peptide sequence was assembled in a linear fashion from the C-terminus to the N-
terminus via manual SPPS based on Fmoc strategy,181 using a Wang resin to assembly 
peptides displaying a free carboxylic acid (1, 3, 4), while a Rink resin was used to 
synthesize peptide amides (2, 5, 6, 7) (Fig. 3.11). 
 
Figure 3.11. Used resins for the synthesis of peptides 1–7. 
 
The Fmoc-protected aminoacids were coupled in the sequence cysteine (Cys), arginine 
(Arg), glycine (Gly), asparagine (Asn) and cysteine (Cys) for the synthesis of petides 1, 2, 3. 
Pbf and Trt side chain protecting groups were selected for their acid lability for Arg and 
Asn respectively. Fmoc-Ahx-OH was coupled with the last Cys in order to obtain the 
precursor linear peptide of 4. On the other hand, the CRGNC sequence was assembled 
after loading the resin with Fmoc-Gly-OH and coupling with Fmoc-Lys(Dde)OH to 
synthesize peptides 5, 6 and 7. 
For the synthesis of C-terminal peptide amides, the first aminoacid was attached using 
the standard peptide coupling procedure, after Fmoc deprotection of the amino function 
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of the MBHA Rink resin. The NovaPEG Rink resin was supplied with the free amino group 
as anchorage point.  
On the other hand, the synthesis of peptide acids, was performed on the Fmoc-Cys 
acetamidomethyl (Acm) preloaded Wang resin to avoid the racemization reaction that is 
likely to occur during the attachment of cysteine with the resin linker bearing a hydroxyl 
group.182 The coupling reactions were carried out by in situ activation of the carboxylic 
function in presence of the uronium/iminium based activating agent HATU and 
diisopropylethylamine. A large excess of the activated aminoacid (5 equivalents with 
respect to the resin loading) was dissolved in DMF to ensure effective diffusion of 
reactants. All the coupling reactions were complete in 2 h as confirmed by a Kaiser 
test.183After each coupling reaction step, Fmoc protecting group removal from the N-
terminus of the growing peptide chain, was achieved by adding a solution of 20% 
piperidine in DMF. This procedure was repeated twice to ensure effective Fmoc 
deprotection, which was monitored by thin layer chromatography, since the formation of 
the dibenzo-fulvene-piperidine adduct strongly adsorbs in the UV range and confirmed by 
a Kaiser test. 
After assembling the aminoacid sequence, simultaneous cleavage of the peptide from the 
resin and removal of side-chain protecting groups were achieved using  a mixture of 
trifluoroacetic acid (TFA) in presence of alkylsilanes and water as scavengers 
(TFA/TIPS/H2O 95:2.5:2.5 v/v/v) to trap carbocations produced by side-chain protecting 
groups. The disulfide bridge formation was performed on resin only for the synthesis of 
compound 4, while it was achieved in solution after the final cleavage of the linear 
peptides for the synthesis of the other compounds.  
All the peptides were purified on a semi-preparative C-18 column on a reverse-phase 
HPLC and then lyophilized and their >98 % purity was confirmed by reverse-phase LC-MS 
analysis. The structures were confirmed by NMR spectroscopy.  
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Synthetic strategy for the synthesis of compounds 1 and 3 
 
The disulphide bridge formation represented a particular challenge for the chemical 
synthesis of the cyclic CNGRC peptide derivatives. 
One single step conversion of S-protected peptides into the corresponding disulphides, is 
one of the most attractive method for S-S bridge formation. 
To this end the acetamidomethyl (Acm) was selected as the -SH protecting group for its 
potential application. Treatment of peptides containing this protecting group with either 
thallium trifluoroacetate in TFA and with iodine in AcOH-H2O mixtures results in the 
simultaneously deprotection of the thiol functions and ring closure. The latter strategy 
has been extensively applied in peptide synthesis although side reactions occurring upon 
iodine treatment. To overcome this problem, the excess of iodine should be quenched. 
The synthetic strategy adopted for compounds 1 and 3 was the cyclization in solution 
phase after the cleavage from the Wang resin of the linear free N-terminus pentapeptide 
9 and acetylated N-terminus 10 respectively (Scheme 3.1). For the synthesis of the 
acetylated N-terminus cCNGRC (3) the acetylation step was performed on resin before 
the cleavage of the linear pentapeptide by using a mixture of DCM/Acetic 
Anhydride/DIPEA. 
Iodine was selected as the oxidizing agent and the reaction was performed in a large 
volume of solvent. High dilution conditions were necessary to promote intramolecular 
disulphide bond formation and to avoid intermolecular dimerization. The crude 
pentapeptide was added dropwise to a solution of iodine in AcOH in presence of HCl. The 
formation of the oxidized product was monitored by RP-HPLC coupled to tandem ESI-MS 
and stopped after 2 h. Diethylethere was used to simultaneously quench and remove the 
excess of iodine and to achieve the precipitation of the cyclic pentapetide, as described in 
literature.184 
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Scheme 3.1 Reagents and conditions: SPPS Fmoc strategy: Fmoc cleavage) 20 % piperidine in DMF, rt, 10 min (×2); 
coupling) Fmoc-amino acid (5 equiv), HATU (4.9 equiv), DIPEA (10 equiv), DMF, rt, 2 h. Sequence of addition: Fmoc-
Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Acm)-OH. (a) DCM/Acetic Anhydride/DIPEA 20:4:1, rt, 1h (x2); 
(b) TFA/TIPS/H2O 95:2.5:2.5, rt, 2 h; (c) I2 (60 equiv) AcOH, HCl, rt, 2 h.  
 
The cyclic peptides 1 and 3 were obtained in acceptable yields, although the high volume 
of solvent represented one of the disadvantages of the above described method.  
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Synthetic strategy for the synthesis of compounds 4 
 
Derivative 4, displaying the free terminal carboxylic function and bearing a biotin tag on 
the N-terminus, was assembled on a preloaded Fmoc-Cys(Acm)Wang resin, as with 
compounds 1 and 3 (Schemes 3.1 and 3.2). 
Fmoc-6-aminohexanoic (ε-Ahx) acid was coupled with the last cysteine bearing an Acm 
protecting group and used as a spacer between the CNGRC peptide and the biotin 
(Scheme 3.2). 
 
Scheme 3.2 Reagents and conditions: SPPS Fmoc strategy: Fmoc cleavage) 20 % piperidine in DMF, rt, 10 min (×2); 
coupling) Fmoc-amino acid (5 equiv), HATU (4.9 equiv), DIPEA (10 equiv), DMF, rt, 2 h. Sequence of addition: Fmoc-
Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Acm)-OH; a) (i) Fmoc-ε-Ahx-OH (5 equiv), DIC (5 equiv), Oxyma 
Pure (5 equiv), DMF, rt, 2 h; (ii) 20 % piperidine in DMF, rt, 10 min (×2); b) I2 (10 equiv), DMF/H2O 4:1, rt, 4 h; c) biotin 
(10 equiv), DIC (10 equiv), Oxyma Pure (10 equiv), DMF, rt, 24 h; (d) TFA/TIPS/H2O 95:2.5:2.5, rt, 2 h. 
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The deprotection/disulphide bridge formation by iodine oxidation was performed on the 
solid support before the coupling of biotin with the ε-amino group of the linker Fmoc-6-
Ahx-OH, because of the high susceptibility of biotin to oxidants. 
The on-resin cyclization step was performed following a procedure described in 
literature,185 by adding to the hexapeptide-resin a solution of 10 equivalents of iodine in a 
mixture of DMF/H2O 4:1 v/v. 
After extensively washing the peptidyl resin with a 2% solution of ascorbic acid in DMF in 
order to quench the excess of iodine, the biotinilation step was performed. Biotin was 
activated in presence of the coupling reagent diisopropilcarbodiimide (DIC) and the 
nucleophile additive oxyma pure, after warming at 60 °C to achieve complete dissolution 
of biotin in DMF, as reported in literature.186 The activated biotin was added to the resin 
and the resulted mixture was allowed to react for 24 h at room temperature. The 
consequent cleavage and purification of the crude biotinylated cyclic peptide gave 
derivative 4 in very low yields. 
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Synthetic strategy for compound 2 
 
In order to improve the cyclization step and the final yield, a different synthetic approach 
was followed for compound 2: the cleavage of the fully deprotected linear pentapeptide 
and the following disulphide bond formation starting from the corresponding -SH 
derivatives (Scheme 3.3). 
 
 
Scheme 3.3. Reagents and conditions: SPPS Fmoc strategy: Fmoc cleavage) 20 % piperidine in DMF, rt, 10 min (×2); 
coupling) Fmoc-amino acid (2 equiv), HATU (1.96 equiv), DIPEA (4 equiv), DMF, rt, 2 h. Sequence of addition: Fmoc-
Cys(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH; a) TFA/TIPS/H2O 95:2.5:2.5, rt, 2 h; 
b) NCS (1 equiv), H2O, rt, 15 min.  
 
To this end the acid-labile trityl (Trt) was selected for the cysteine S-protecting group. The 
CNGRC sequence 13 was assembled on a NovaPEG Rink Amide resin using HATU as 
coupling agent as described in the general procedure. After Fmoc removal of the last 
cysteine, treatment with TFA cleavage mixture gave the fully deprotected linear amide 
peptide 14 (Scheme 3.3). 
The oxidation of free thiol groups was achieved in aqueous medium by adding one 
equivalent of N-chlorosuccinimide (NCS) in 15 min at room temperature, according to a 
procedure reported by Postma and Albericio.187 The crude cyclic peptide was lyophilized, 
analyzed by LC-MS and subsequently purified by RP-HPLC to afford the pure product in 
good yield. 
This strategy overcame the problems associated with the use of strong oxidants such as 
iodine either in solid and in solution phases and the pseudodilution limitations of solid-
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phase disulphide formation. Furthermore aqueous NCS oxidation resulted in an efficient 
and rapid synthetic approach. 
 
Synthetic strategy for C-terminus conjugated peptides 5—7 
 
Taking into account the advantages of the synthetic strategy followed for compound 2, a 
similar approach based on the use of the acid-labile p-methoxytrityl (Mmt) as the cysteine 
S-protecting group was exploited for conjugates 5—7. Peptide 16 was assembled on a 
MBHA Rink resin HL, while peptide 17 was assembled on a NovaPEG Rink amide resin as 
showed in Scheme 3.4.  
 
Scheme 3.4. Reagents and conditions: SPPS Fmoc strategy: Fmoc cleavage) 20 % piperidine in DMF, rt, 10 min (×2); 
coupling) Fmoc-amino acid (2 equiv), HATU (1.96 equiv), DIPEA (4 equiv), DMF, rt, 2 h. Sequence of addition: Fmoc-Gly-
OH,Fmoc-Lys(Dde)-OH, Fmoc-Cys(Mmt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Boc-Cys(Mmt)-OH; a) 
2% NH2NH2 in DMF, rt, 3 min (×2) ; b) biotin (2 equiv), HATU (1.96 equiv), DIPEA (4 equiv), DMF, rt, 2 h (x 2); c) Oregon 
green 488 (2 equiv), HATU (1.96 equiv), DIPEA (4 equiv), DMF, rt, 2 h; d) TFA/TIPS/H2O 95:2.5:2.5, rt, 2 h; e) atmospheric 
O2, 50 mM PB, pH 7.2, rt, 72 h; f) NCS (1 equiv), H2O/CH3CN 9:1, rt, 15 min; g) acetic anhydride (3.4 equiv), H2O, rt, 10 
min. 
 
75 
 
 
The assembling of the CRGNC sequence was performed after loading the resin with Fmoc-
Gly-OH and coupling with Fmoc-Lys(Dde)OH. The Lys side chain bearing an amino group 
was selected as the anchorage point for biotin (derivatives 5 and 6) and fluorescent probe 
(derivative 7) conjugation. 1-(4,4-Dimethyl-2,6-dioxacyclohexylidene)ethyl (Dde) was used 
as protecting group for the –NH2 function of lysine side chain, for its stability under Fmoc 
deprotection conditions.188 On the other hand, Fmoc protecting group is readily 
deprotected under the classical Dde cleavage conditions (2% v/v hydrazine in DMF).  
Therefore an acid-labile Boc protective group was used for the heptapeptide N-terminus 
in order to achieve an orthogonal protection between the lysine side chain and the α-
amino group of the last aminoacid of the sequence.  
For this purpose a cysteine bearing the acid-labile Boc and Mmt protective groups, for 
amino and thiol functions respectively (Boc-Cys(Mmt)-OH), was prepared (Scheme 3.5). 4-
Methoxytritylalcohol readily condensed with the primary -SH group of the cysteine in 
presence of boron trifluoride (BF3) in AcOH as catalyst, according to a procedure reported 
in literature,189 to afford the intermediate 18 (Scheme 3.4), which subsequently was 
allowed to react with di-tert-butyl dicarbonate to yield the Boc-Cys(Mmt)-OH derivative. 
 
 
 
Scheme 3.5. Reagents and conditions a) 4-methoxytrityl alcohol, BF3, AcOH; b) Boc2O, Na2CO3, 1,4-dioxane. 
 
After the last aminoacid of the heptapeptide sequence (15) was added, the orthogonal 
protecting group of lysine (Dde) was removed with hydrazine and conjugation with biotin 
or 5(6)-carboxy-2′,7′-difluorofluorescein (Oregon green 488; OG), was accomplished on-
resin through the amino function of the lysine side-chain, using HATU as coupling agent, 
to give intermediates 16 and 17, respectively. The coupling reaction was repeated twice 
to ensure effective peptide conjugation. For the synthesis of intermediate 16, warming at 
80 °C was necessary to completely dissolve biotin in DMF before adding the coupling 
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agent and the tertiary amine. The solution of activated biotin was then added to the resin 
at room temperature. After cleavage of the biotinylated precursor 16 from the resin, 
conjugates 5 and 6 were prepared forming the disulphide bond by air oxidation. Indeed, 
since in a first attempt treatment of biotinylated linear peptides with NCS resulted in a 
mixture of undesired by-products, milder oxidation conditions were necessary. The crude 
linear peptide was dissolved in 50 mM phosphate buffer (pH 7.2) and the solution was 
stirred while bubbling air through it. The disulphide bridge formation was monitored by 
LC-MS and was complete in 72 h. After aqueous medium concentration, the resulting 
white precipitate (compound 5) was collected and washed several times with H2O and 
ACN and no further purification was needed. This synthetic route gave the best final yield.  
Treatment of compound 5 with acetic anhydride quantitatively afforded derivative 6, 
which was purified by semi-preparative RP-HPLC. 
Before conjugation of the linear CNGRCKG peptide with OG, the synthesis of the 
fluorescent dye was performed. OG was selected as the fluorescent probe for its 
advantages over fluorescein dyes: conjugates of the OG fluorophore are more 
photostable and moreover their fluorescence is not appreciably quenched, even at high 
degrees of labelling. 
The reaction between 4-fluororesorcinol and trimellitic anhydride in methanesulfonic acid 
gave a mixture of OG 5- and 6-regioisomers (Scheme 3.6),190 which was then used for on-
resin peptide conjugation (intermediate 17, Scheme 3.4). 
 
 
 
 
Scheme 3.6 
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Precursor 17 was cleaved from the solid support and the desired conjugate 7 was 
obtained performing the cyclization step in solution phase using NCS, in less than 15 
minutes (Scheme 3.4). The crude peptide was obtained as a mixture of isomers 7a e 7b 
(Figure 3.12) which were separated by semi-preparative RP-HPLC, using isocratic elution 
conditions (26% ACN 0.1% TFA in H2O 0.1 % TFA). The OG conjugated peptide was 
obtained with a 25 % yield, based on the estimated loading of the resin and appeared as 
an orange powder. 
 
 
 
Figure 3.12 
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3.3.2. Biology 
APN inhibition assay180 
 
The cCNGRC peptide 1 and its derivatives 2−6 were examined for their inhibitory activity 
toward porcine APN using a spectrophotometric assay commonly employed for screening 
APN inhibitors.177,191,192 
APN obtained from porcine kidneys microsomes, (activity = 15 units/mg) was used for its 
high grade of omology with the human enzyme. 
APN and the substrate L-leucine-p-nitroanilide were incubated for 1 h in the presence of 
gradient concentrations of peptides 1−6 and formation of the product p-nitroaniline was 
measured reading absorbance at 405 nm (Figure 3.13). 
 
  
 
Figure 3.13. Schematic representation of the reaction catalyzed by APN in the biological assay. 
 
The APN inhibitor bestatin was used as a positive control, while biotin as a negative one. 
The results of the assay show the effects of C- or N-terminus functionalization on the 
activity of 1. In accordance with data previously reported,191 the inhibitory potency of 1 
was considerably lower than that of bestatin (about 120-fold). Replacement of the C-
terminus COOH of 1 with a CONH2 function (derivative 2) had negligible effect on the 
inhibitory potency of the parent peptide (Table 3.1 and Figure 3.14 a, b). Conversely, the 
activity was markedly impaired upon N-terminus acetylation (compound 3) or by 
conjugation of amino function to a biotinylated linker (compound 4). As shown in Figure 
3.14 a), at a concentration of 1.25 mM of peptides 3 and 4 the inhibition of APN activity 
was less than 30%. Interestingly, bioconjugate 5 (consisting of biotin fused through a 
lysine linker to the C-terminus of 1) showed an increased inhibitory potency relative to 
the parent peptide 1 (almost 15-fold, Table 3.1). The latter result is in accordance with 
the IC50 value of 38.7 μM reported in the literature163 for the c(CNGRC)G peptide, 
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suggesting that an additional amino acid directly linked to the C-terminus of cCNGRC 
peptides can lead to an increase of APN inhibitory potency. 
 
Table 3.1. IC50 values of bestatin and NGR peptides 1-6.a 
 
compound IC50(µM) 
Bestatin 5.1 
1 636 
2 620 
3 >1000 
4 >1000 
5 43.3 
6 >1000 
a IC50 values were calculated from concentration-response curves by a nonlinear regression analysis using GraphPad Prism Software.  
 
 
  
Figure 3.14. Results of enzyme inhibition assays. Effect of bestatin (25 µM), biotin (1.25 mM) and peptides 1–6 (1.25 
mM) on the enzymatic activity of APN. The results are expressed as percentage of APN residual activity relative to the 
catalytic activity of APN in the absence of any inhibitor taken as 100%; (b) inhibition of APN by peptides 1 and 2; (c) 
inhibition of APN by peptides 3, 5 and 6. Data are the average of two independent experiments performed in duplicate, 
with error bars displaying standard deviations. 
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Similarly to what was previously observed with the N-acetylated derivative 3, acetylation 
of the free N-terminus of peptide 5 significantly impaired the activity of the resulting C-
biotinylated compound 6 (Figure 3.14 a, c).  
Overall, these results show that the C-terminus is the optimal “handle” for cCNGRC 
peptides derivatization, whereas the N-terminus must remain in free NH2 form for 
achieving higher APN inhibitory activity.  
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APN inhibition assay on HT1080 cells180  
 
To further confirm the results of the enzymatic assay in a more physiological system, the 
inhibitory activities of C-derivatives 2 and 5 and the corresponding N-acetylated 
derivatives 3 and 6 toward human APN expressed on the surface of living cells were also 
evaluated. Human fibrosarcoma cell line (HT1080) is known to express high levels of APN 
and has been extensively used to measure human APN activity. Adherent HT1080 cells 
and the substrate L-leucine-p-nitroanilide were incubated for 1 h in the presence of 
gradient concentrations of inhibitors and formation of the product p-nitroaniline was 
measured on a plate reader at 405 nm. Bestatin was included in the test as a positive 
control. As shown in Figure 3.15, the inhibitory activities of the tested compounds exactly 
replicated the results obtained with the purified enzyme.  
 
Figure 3.15. Results of APN inhibition assays on cells. Inhibition of APN expressed on HT1080 cells by bestatin (25 µM) 
and NGR inhibitors (1.25 mM). The results are expressed as percentage of APN residual activity relative to the untreated 
control (100%). The data are the average of three replicates ± standard deviation. 
 
The N-acetylated derivative 3 showed reduced activity compared to 2, while the C-
biotinylated 5 displayed the highest inhibitory potency of the series. The activity of the N-
acetylated derivative 6 was significantly reduced, in complete agreement with the results 
previously obtained with the purified enzyme. 
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Imaging of APN in HT1080 cells with c(CNGRC)KG-OG (7)180 
 
Bioconjugate 7, a cCNGRC peptide carrying the OG 488 as a fluorescent probe at the C-
terminus was used to image APN in living cells. Oregon green was selected as fluorescent 
probe because its high quantum efficiency and resistance to photobleaching make it a 
good and flexible tool for both wide-field and confocal imaging.190 To decide the best 
concentration for APN detection on HT1080, cells were incubated at 0 °C for 1 h, then 
fixed and imaged under a fluorescent microscope at 20× magnification. The fluorescent 
signal of 7 was saturable and approached the maximum at a concentration of 100 μM 
(Figure 3.16 a, b).  
 
 
 
Figure 3.16. Tracer binding studies of c(CNGRC)KG-OG 7 on HT1080 cells. a) Binding curve of c(CNGRC)KG-OG 7 on 
HT1080 human fibrosarcoma cells. b) Incubation with tracer 7 shows binding to HT1080 cells. c) Quantification of the 
fluorescent signal present in the cells showing that the binding of tracer 7 to HT1080 cells is effectively inhibited by co-
incubation with bestatin (100 µM) and c(CNGRC)KG-biotin 5 (1 mM).  
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The binding of the fluorescent probe was greatly reduced in the presence of bestatin (100 
μM) or cCNGRCKG-biotin 5 (1 mM), confirming that the binding is indeed through APN 
(Figure 3.16 c). 
It has been shown that APN is rapidly internalized after binding on the cell surface.193 The 
internalization is fundamental for some of the APN functions and is exploited by some 
coronavirus to enter and infect epithelial cells.194 In addition APN internalization has been 
used to specifically target cancer cells with NGR conjugated to cytotoxic agents. Also the 
ability of the fluorescent probe 7 to undergo APN mediated endocytosis was analyzed. As 
shown in Figure 3.17 the fluorescent conjugate 7 is fully internalized and present in 
intracellular vesicles after 1 h at 37 °C. 
 
Figure 3.17. Internalization of the conjugate 7 via APN-mediated endocytosis. 
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3.4. Conclusions 
In the context of NGR tumor-homing peptides, the cyclic CNGRC peptide has been used as 
carrier for delivery of drugs and imaging probes into tumors in several studies. This work 
was focused on exploiting the structural requirements of this cyclic peptide for effective 
APN binding. In particular the role of N-terminal amine group of the cCNGRC in the APN 
binding process was unclear. Recognition of the contribution of this group to the binding 
is of remarkable importance for the rational design of cCNGRC-based bioconjugates as 
effective tools for tumour targeting. Therefore our attention was focused on the right 
functionalization site of this cyclic peptide.  
To this aim, the basic structure of the cyclic peptide with the free N and C termini, peptide 
1 and a small library of cCNGRC peptides differently functionalised on the N-terminus and 
on the C-terminus was synthesized. An efficient solid-phase synthesis of cCNGRC peptides 
and conjugates carrying different functional tags on either the amino- or the carboxyl-
terminus, which could be prepared in a hundreds of mgs scale, has been developed. 
The effect of the structural modifications on the APN inhibitory potency was investigated 
by means an APN inhibition assay either on the purified porcine APN enzyme and in a 
human cancer cell line (HT1080). Only peptides with the free amino group were able to 
inhibit APN activity, therefore the free amino terminus is important for the APN 
recognition and the C-terminus is the optimal site for the formation of CNGRC-based 
derivatives with retained activity towards APN.  
A fluorescent CNGRC-based probe, consisting of OG-488 fused through a lysine linker to 
the C-terminus of CNGRC, was synthesised and used to image APN expression on HT1080 
cells. 
Biological studies showed the cellular uptake of the fluorescent conjugate. It will be used 
for further molecular imaging studies. 
Since (1) the porcine APN residues involved in the binding to cCNGRC peptides are 
completely conserved between human and porcine APNs, and (2) APN inhibitory activity 
of peptides 1–6 and cell internalization capacity of 7 were also confirmed on human cells, 
these results should be translatable to the development of more efficient cCNGRC 
constructs and conjugates carrying toxic payloads or radioisotopes for pre-clinical and 
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clinical use. These findings can guide the future development of new NGR bioconjugates 
and peptidomimetics with high affinity for APN. 
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CHAPTER 4 
4. Experimental section 
4.1. Experimental data for Chapter 2 
4.1.1. Chemistry 
General methods 
All the compounds prepared were at least 98% pure as determined by combustion 
analysis. Melting points are uncorrected. TLC was performed on Bakerflex plates (Silica 
gel IB2-F) and column chromatography on Kieselgel 60 (Merck): the eluent was a mixture 
of petroleum ether/acetone in various proportions. IR spectra were recorded in nujol on a 
Nicolet Avatar 320 E.S.P.; ν max is expressed in cm-1. 1H-NMR spectra were recorded on a 
Varian MR 400 MHz (ATB PFG probe); the chemical shift (referenced to solvent signal) is 
expressed in δ (ppm) and J in Hz (abbreviations: ar=aromatic, im=imidazole, ph=phenyl, 
py=pyridine, pym=pyrimidine, th=thiazole, imi=imidazoline). The IR, 1H-NMR and 13C-NMR 
spectra of the compounds are in agreement with the assigned structures. 2,4-
diaminopyrimidine 11 is commercially available. The following compounds were prepared 
according to the literature: 2-bromo-1-(thiophen-3-yl)ethan-1-one,19514a,121, 15,196, 20,197 
21,198and 25.124 
 
Synthesis of 2-(thiophen-3-yl)imidazo[1,2-a]pyrimidin-7-amine (12b) 
 
2,4-Diaminopyrimidine 11 (10 mmol) was dissolved in 40 mL of acetone and treated with 
2-bromo-1-(thiophen-3-yl)ethan-1-one (15 mmol). The reaction mixture was refluxed for 
3h and the resulting precipitate (12b hydrobromide) was collected by filtration. The free 
base was obtained by treatment with 15% NH4OH. The resulting precipitate was collected 
by filtration and crystallized from ethanol.  
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Yield 46%; mp 285-290 °C; IR (cm-1): 3148, 1667, 1087, 846, 720; 1H-NMR (400 MHz, 
DMSO-d6): δ = 8.36 (1H, d, pym, J =7.6), 7.80 (1H, dd, th, J =2.6, J =1.2), 7.74 (1H, s, im), 
7.57 (1H, dd, th, J =5.2, J =2.6), 7.48 (1H, dd, th, J =5.2, J =1.2), 7.16 (2H, s, NH2), 6.37 (1H, 
d, pym, J=7.6). Anal. Calcd for C10H8N4S (MW 216.26): C, 68.90; H, 5.14; N, 4.46. Found: C, 
69.04; H, 5.02; N, 4.78. 
 
Synthesis of 2,8-di(thiophen-3-yl)diimidazo[1,2-a:1',2'-c]pyrimidine (13b) 
 
Compound 12b (5 mmol) was dissolved in ethanol (40 mL), treated with excess of 2-
bromo-1-(thiophen-3-yl)ethan-1-one (20 mmol) and kept under reflux for 7h. The 
resulting compound 13b.hydrobromide was collected by filtration and treated with 15% 
NH4OH in order to prepare the free base which was collected by filtration and crystallized 
from ethanol.  
Yield 12%, mp 245-249 °C dec; IR (cm-1): 1635, 1292, 1193, 852, 724; 1H-NMR (400 MHz, 
DMSO-d6): δ = 8.61 (1H, s, im), 8.28 (1H, d, pym, J =7.6), 8.09 (1H, s, im), 7.99 (1H, dd, th, J 
=3.0, J =1.2), 7.83 (1H, dd, th, J =3.0, J =1.2), 7.75 (1H, dd, th, J =5.0, J =1.2), 7.65 (1H, dd, 
th, J =5.0, J =3.0), 7.63 (1H, dd, th, J =5.0, J =3.0), 7.56 (1H, dd, th, J=5.0, J =1.2), 7.16 (1H, 
d, pym, J =7.6). Anal. Calcd for C16H10N4S2 (MW 322.41): C, 59.61; H, 3.13; N, 17.38. 
Found: C, 60.03; H, 3.67; N, 17.99. 
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Synthesis of 1,7-dimethyl-5,7-dihydropyrrolo[3,2-f]indole-2,6(1H,3H)-dione (16) 
 
 
 
Compound 15 (10 mmol) was dissolved in toluene (20 mL) and treated with a solution of 
NaOH (20 mmol) in H2O (4 mL). Chloroacetyl chloride (20 mmol) was added dropwise at 
0-15°C. The reaction mixture was kept for 3 h at room temperature. The aqueous phase 
was removed and the organic layer was washed with HCl 2N and with H2O. Toluene was 
removed under reduced pressure and the resulting residue was treated with AlCl3 (10 g) 
at 160°C for 6 h. The mixture was then poured onto ice. The crude compound 16 was 
collected by filtration and crystallized from ethanol. Yield 45%; mp 275 °C dec; IR (cm-1): 
1705, 1625, 1276, 1025, 641; 1H-NMR (400 MHz, DMSO-d6): δ = 7.13 (1H, s, ar), 6.76 (1H, 
s, ar), 3.48 (4H, s, CH2), 3.14 (6H, s, CH3). Anal. Calcd for C12H12N2O2 (MW 216.24): C, 
66.65; H, 5.59; N, 12.96. Found: C, 68.03; H, 6.05; N, 13.11. 
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General procedure for the synthesis of the aldehydes 14b and 17, 22, 23  
 
The Vilsmeier reagent was prepared at 0-5°C by dropping POCl3 (54 mmol) into a stirred 
solution of DMF (65 mmol) in CHCl3 (5 mL). The appropriate starting compound (13b, 16, 
20, 21, 5 mmol) was suspended in CHCl3 (20 mL). The mixture thus obtained was dropped 
into the Vilsmeier reagent while maintaining stirring and cooling. The reaction mixture 
was kept for 3 h at room temperature and under reflux for 2-40 h (according to a TLC 
test). Chloroform was removed under reduced pressure, the resulting oil was poured 
onto ice and the precipitate thus obtained was collected by filtration. The crude 
aldehydes 14b and 17 were crystallized from ethanol. The aldehydes 22 and 23 were 
isolated by column chromatography (petroleum ether/acetone, 70/30). 
 
2,8-Di(thiophen-3-yl)diimidazo[1,2-a:1',2'-c]pyrimidine-3,9-dicarbaldehyde(14b). 
 
Yield 99%; mp 242-247 °C dec; IR (cm-1): 1662, 1627, 1319, 866, 794; 1H-NMR (400 MHz, 
DMSO-d6): δ = 11.38 (1H, s, CHO), 10.25 (1H, s, CHO), 9.21 (1H, d, pym, J=7.8), 8.90 (1H, 
dd, th, J=3.0, J=1.2), 8.44 (1H, dd, J=2.4, J=1.2), 7.99 (1H, dd, th, J=5.2, J=1.2), 7.80 (2H, m, 
th), 7.68 (1H, dd, th, J=5.2, J=3.0), 7.57 (1H, d, pym, J=7.8). Anal. Calcd for C18H10N4O2S2 
(MW 378.43): C, 57.13; H, 2.66; N, 14.81. Found: C, 56.98; H, 2.74: N, 15.01. 
 
2,6-Dichloro-1,7-dimethyl-1,7-dihydropyrrolo[3,2-f]indole-3,5-dicarbaldehyde(17) 
 
Yield 85%; mp 300 °C dec; IR (cm-1): 1644, 1506, 1096, 1049, 718; 1H-NMR (400 MHz, 
CF3COOD): δ =9.82 (2H, s, CHO), 9.02 (1H, s, ar), 7.79 (1H, s, ar), 4.12 (6H, s, CH3). 
Anal. Calcd for C14H10Cl2N2O2 (MW 309.15): C, 54.39; H, 3.26; N, 9.06. Found: C, 56.22; H, 
2.99; N, 8.98. 
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2-Chloro-1-methyl-1H-indole-3,6-dicarbaldehyde(22). 
 
Yield 2%; mp 181-183 °C; IR (cm-1):1700, 1686, 1646, 1154, 722; 1H-NMR (400 MHz, 
DMSO-d6): δ = 10.07 (1H, s, CHO), 10.03 (1H, s, CHO), 8.24 (1H, d, ind-7, J =1.2), 8.23 (1H, 
d, ind-4, J =8.4), 7.83 (1H, dd, ind-5, J=8.4, J =1.2), 3.93 (3H, s, CH3). Anal. Calcd for 
C11H8ClNO2 (MW 221.64): C, 59.61; H, 3.64; N, 6.32. Found: C, 60.04; H, 3.87; N, 5.98. 
 
2-Chloro-1-phenyl-1H-indole-3,6-dicarbaldehyde(23). 
 
Yield 7%; mp 190-195 °C; IR (cm-1): 1654, 1608, 1151, 827, 725; 1H-NMR (400 MHz, 
DMSO-d6): δ = 10.16 (1H, s, CHO), 10.00 (1H, s, CHO), 8.36 (1H, d, ind-4, J =8.4), 7.89 (1H, 
dd, ind-5, J =8.4, J =1.6), 7.71 (5H, m, ph), 7.66 (1H, d, ind-7, J =1.6). 
Anal. Calcd for C16H10ClNO2 (MW 283.71): C, 67.74; H, 3.55; N, 4.94. Found: C, 68.02; H, 
3.86; N, 5.08. 
  
91 
 
 
General procedure for the synthesis of hydrazones 2-5 and 6-10  
The appropriate aldehyde or ketone (5 mmol) was dissolved in ethanol and treated with 
two equivalents of : 
- 2-hydrazino-2-imidazoline hydrobromide solubilised in ethanol (compounds 2 and 3); 
- 2-hydrazinopyridine solubilized in ethanol and treated with hydrochloridric acid 
(compounds 4 and 10); 
- aminoguanidinehydrogencarbonatsuspended in ethanol and treated with 
hydrochloridric acid in order to achieve a solution (compounds 5–9). 
The reaction mixture was refluxed for 15-30 h according to a TLC test and the resulting 
precipitate was collected by filtration and crystallized from ethanol. Compound 3 was 
obtained as a precipitate from the filtered solution. 
 
3,9-Bis((2-(4,5-dihydro-1H-imidazol-2-yl)hydrazono)methyl)-2,8-diphenyldiimidazo[1,2-
a:1',2'-c]pyrimidine dihydrobromide (2) 
 
 
 
Yield 22%; mp 300 °C; IR (cm-1): 3360, 1655, 1071, 938, 718; 1H-NMR (400 MHz, DMSO-
d6): δ = 12.50 (2H, broad, NNH), 9.49 (1H, s, CH), 9.30 (1H, d, pym, J=8.0), 8.80 (2H, 
broad,NH/NH+imi), 8.64 (1H, s, CH), 8.29 (2H, broad, NH/NH+imi), 8.12 (2H, d, ph, J =8.2), 
7.84 (2H, d, ph, J =8.2), 7.58 (3H, m, ph), 7.49 (3H, m, ph), 7.37 (1H, d, pym, J=8.0), 3.81 
(4H, s, CH2), 3.72 (4H, s, CH2); 13C-NMR (101 MHz, DMSO-d6): δ = 157.68, 157.07, 146.45, 
145.73, 142.16, 140.22, 139.77, 139.73, 132.70 , 131.80, 129.51, 129.22, 129.07, 128.97, 
128.87, 128.38, 128.00, 117.74, 115.28, 103.69, 42.92, 42.82. Anal. Calcd for 
C28H26N12.2HBr (MW 692.43): C, 48.57; H, 4.08; N, 24.27. Found: C, 48.93; H, 3.95; N, 
24.87. 
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9-((2-(4,5-Dihydro-1H-imidazol-2-yl)hydrazono)methyl)-2,8-diphenyldiimidazo[1,2-a:1',2'-
c]pyrimidine-3-carbaldehyde hydrobromide(3).  
 
Yield 50%; mp 320 °C; IR (cm-1): 3321, 1668, 1625, 774, 699; 1H-NMR (400 MHz, DMSO-
d6): δ = 12.71 (1H, broad, NNH), 10.09 (1H, s, CHO), 9.47 (1H, s, CH), 9.12 (1H, d, pym, J 
=7.4), 8.29 (2H, broad,NH/NH+imi), 8.12 (2H, m, ph), 8.03 (2H, m, ph), 7.61 (3H, m, ph), 
7.52 (1H, d, pym, J =7.4), 7.50 (3H, m, ph), 3.72 (4H, s, CH2); 13C-NMR (101 MHz, DMSO-
d6): δ = 180.42, 157.71, 152.81, 145.94, 142.39, 140.47, 139.92, 132.51, 131.02, 130.17, 
129.63, 129.52, 129.01, 128.95, 128.01, 126.27, 120.24, 117.91, 105.05, 42.93. Anal. Calcd 
for C25H20N8O.HBr (MW 529.39): C, 56.72; H, 4.00; N, 21.17. Found: C, 57.03; H, 3.89; N, 
21.84. 
 
2,8-Diphenyl-3,9-bis((2-(pyridin-2-yl)hydrazono)methyl)diimidazo[1,2-a:1',2'-c]pyrimidine 
dihydrochloride (4).  
 
Yield 71%; mp 267-270 °C; IR (cm-1): 3380, 1651, 1612, 1276, 707; 1H-NMR (400 MHz, 
DMSO-d6): δ = 13.13 (1H, broad, NNH), 12.82 (1H, broad,NNH), 9.64 (1H, s, CH), 9.56 (1H, 
d, pym, J =8.0), 8.83 (1H, s, CH), 8.22 (1H, d, py, J =6.0), 8.14 (2H, d, ph, J =7.2), 8.09 (1H, 
d, py, J =6.0), 8.06 (1H, t, py, J =8.4), 7.95 (1H, t, py, J =8.4), 7.93 (2H, d, ph, J =7.2), 7.56 
(2H, t, ph, J =7.2), 7.43-7.53 (4H, m, 3H ph+1H py), 7.40 (1H, d, py, J =8.4), 7.28 (1H, d, py, 
J =8.4), 7.17 (1H, d, pym, J =8.0), 7.08 (1H, t, ph, J =7.2), 7.00 (1H, t, py, J =6.0), 3.75 (2H, 
broad, NH+py); 13C NMR (151 MHz, DMSO-d6) δ = 146.08, 144.90, 141.83, 139.66, 133.15, 
131.81, 129.31, 129.08, 129.03, 128.87, 128.68, 128.39, 127.91, 118.85, 115.53, 114.96, 
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114.59, 111.67, 103.76. Anal. Calcd for C32H24N10.2HCl (MW 621.52): C, 61.84; H, 4.22; N, 
22.54. Found: C, 62.05; H, 4.59; N, 22.87. 
 
2,2'-((2,8-Di(thiophen-3-yl)diimidazo[1,2-a:1',2'-c]pyrimidine-3,9 
diyl)bis(methanylylidene))bis(hydrazine-1-carboximidamide) dihydrochloride (5) 
 
Yield 98%; mp 265-269 °C dec; IR (cm-1): 3358, 1675, 1623, 1149, 866; 1H-NMR (400 MHz, 
DMSO-d6): δ = 12.57 (1H, s, NNH), 12.02 (1H, s, NNH), 9.69 (1H, s, CH), 9.26 (1H, d, pym, J 
=8.0), 8.82 (1H, s, CH), 8.47 (1H, dd, th, J =2.8, J =1.2), 8.26 (1H, dd, th, J =2.8, J =1.2), 7.81 
(1H, dd, th, J =5.2, J =2.8), 7.78 (1H, dd, th, J =5.2, J =1.2), 7.76 (1H, dd, th, J =5.2, J =1.2), 
7.69 (8H, broad, NH2/NH2+), 7.66 (1H, dd, th, J =5.2, J =2.8), 7.28 (1H, d, pym, J =8.0);  
13C-NMR (101 MHz, DMSO-d6): δ = 155.20, 154.67, 142.05, 141.77, 141.27, 139.57, 
139.19, 138.43, 134.00, 133.95, 128.56, 128.44, 127.77, 127.45, 126.88, 126.32, 125.72, 
117.54, 114.63, 103.26. Anal. Calcd for C20H18N12S2.2HCl (MW 563.49): C, 42.63; H, 3.58; 
N, 29.83. Found: C, 42.97; H, 3.02; N, 30.05. 
 
2,2'-((2,6-Dichloro-1,7-dimethyl-1,7-dihydropyrrolo[3,2-f]indole-3,5-
diyl)bis(methanylylidene))bis(hydrazine-1-carboximidamide)dihydrochloride(6) 
 
Yield 50%; mp 350 °C dec; IR (cm-1): 3329, 1643, 1516, 1148, 1096; 1H-NMR (400 MHz, 
DMSO-d6): δ = 11.70 (2H, broad, NNH), 8.68 (1H, s, ar), 8.47 (2H, s, CH), 7.88 (1H, s, ar), 
7.60 (8H, broad, NH2/NH2+),3.88 (6H, s, CH3); 13C-NMR (101 MHz, DMSO-d6): δ = 154.53, 
143.06, 134.61, 130.97, 119.67, 112.71, 105.66, 91.84, 30.65. Anal. Calcd for 
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C16H18Cl2N10.2HCl (MW 494.21): C, 38.89; H, 4.08; N, 28.34. Found: C, 39.03; H, 3.87; N, 
28.84. 
 
2,2'-((2-Chloro-1-methyl-1H-indole-3,6-diyl)bis(methanylylidene))bis(hydrazine-1-
carboximidamide) dihydrochloride (7) 
 
Yield 75%; mp 235-240 °C; IR (cm-1): 3150, 1670, 1605, 1129, 934; 1H-NMR (400 MHz, 
DMSO-d6): δ = 12.08 (2H, broad, NNH), 8.38–8.34 (2H, m, ind), 8.30 (1H, s, CH), 8.15 (1H, 
s, CH), 7.70 (8H, broad, NH2/NH2+gua), 7.67 (1H, d, ind, J =7.8), 3.85 (3H, s, CH3); 13C-NMR 
(101 MHz, DMSO-d6): δ = 155.44, 154.86, 147.32, 141.62, 136.15, 131.93, 128.72, 124.42, 
121.95, 121.59, 109.60, 106.59, 30.57. Anal. Calcd for C13H16ClN9.2HCl (MW 406.70): C, 
38.39; H, 4.46; N, 31.00. Found: C, 38.78; H, 4.73; N, 29.02. 
 
2,2'-((2-Chloro-1-phenyl-1H-indole-3,6-diyl)bis(methanylylidene))bis(hydrazine-1-
carboximidamide) dihydrochloride (8) 
 
Yield 67%; mp 350 °C dec; IR (cm-1): 3163, 1666, 1631, 1158, 934; 1H-NMR (400 MHz, 
DMSO-d6): δ = 12.11 (2H, broad, NNH), 8.48 (1H, d, ind-4, J =8.6), 8.47 (1H, s, CH), 8.25 
(1H, s, CH), 7.88 (d, ph, J = 8.5 Hz, 2H), 7.85 – 7.60 (m, 10 H), 7.58 (d, ph, J = 8.1 Hz, 2H), 
7.49 (s, 1H); 13C-NMR (101 MHz, DMSO-d6): δ = 155.37, 154.93, 147.71, 141.50, 136.74, 
134.31, 131.33, 129.98, 129.55, 129.47, 128.16, 124.54, 122.39, 121.45, 110.57, 108.16. 
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Anal. Calcd for C18H18ClN9.2HCl (MW 468.77): C, 46.12; H, 4.30; N, 26.89. Found: C, 45.97; 
H, 4.78; N, 27.02. 
 
2,2'-(2E-1,1'-dimethyl-[2,2'-biindolinylidene]-3,3'-diylidene)bis(hydrazine-1-
carboximidamide)dihydrochloride (9) 
 
Yield 32%; mp 315-320 °C; IR (cm-1): 3326, 1667, 1571, 1041, 722; 1H-NMR (400 MHz, 
DMSO-d6): δ = 12.48 (2H, s, NNH), 8.52 (8H, broad, NH2/NH2+), 7.75 (2H, d, ind, J =7.6), 
7.49 (2H, t, ind, J =7.6), 7.18 (2H, t, ind, J 7.6), 7.16 (2H, d, ind, J =7.6), 3.22 (6H, s, CH3); 
13C-NMR (101 MHz, DMSO-d6): δ = 160.18, 155.88, 144.09, 136.26, 132.08, 123.00, 
121.31, 118.88, 109.94, 25.79. Anal. Calcd for C20H22N10.2HCl (MW 475.38): C, 50.53; H, 
5.09; N, 29.46. Found: C, 50.98; H, 4.86; N, 29.78. 
 
2E-1,1'-dimethyl-3,3'-bis(2-(pyridin-2-yl)hydrazono)-2,2'-biindolinylidene dihydrochloride 
(10)  
 
Yield 25%; mp 255-260 °C; IR (cm-1):3397, 1685, 1638, 1117, 1043; 1H-NMR (400 MHz, 
DMSO-d6): δ = 12.84 (2H, s, NNH), 8.32 (2H, m, ind), 7.97 (2H, t,ind, J =7.6), 7.67 (4H, m, 
ind+py), 7.42 (2H, t, ind, J =7.6), 7.16 (6H, m, py), 3.72 (2H, broad, NH+ py), 3.26 (6H, s, 
CH3); 13C-NMR (101 MHz, DMSO-d6): δ = 161.25, 154.46, 147.83, 142.02, 139.17, 129.57, 
129.31, 122.65, 119.76, 119.04, 118.60, 109.54, 107.53, 25.58. Anal. Calcd for 
C28H24N8.2HCl (MW 545.47): C, 61.65; H, 4.80; N, 20.54. Found: C, 61.20; H, 5.02; N, 20.12. 
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4.1.2. Biophisical evaluation 
 
Oligonucleotide synthesis and sample preparation 
The DNA sequences were synthesized using standard ß-cyanoethylphosphoramidite solid 
phase chemistry on an ABI 394 DNA/RNA synthesizer (Applied Biosystem) at the 5-µmol 
scale. DNA detachment from support and deprotection were performed by treatment 
with concentrated ammonia aqueous solution at 55 °C for 12 h. The combined filtrates 
and washings were concentrated under reduced pressure, dissolved in water, and 
purified by high-performance liquid chromatography (HPLC) on a Nucleogel SAX column 
(Macherey-Nagel, 1000-8/46), using buffer A consisting of 20 mM KH2PO4/K2HPO4 
aqueous solution (pH 7.0), containing 20% (v/v) CH3CN, buffer B consisting of 1 M KCl, 20 
mM KH2PO4/K2HPO4 aqueous solution (pH 7.0), containing 20% (v/v) CH3CN, and a linear 
gradient from 0% to 100% B for 30 min with a flow rate 1 mL/min. The fractions of the 
oligomers were collected and successively desalted by Sep-pak cartridges (C-18). The 
isolated oligomer was proved to be >98% pure by NMR. In particular, the following 
oligonucleotides have been synthesized: d[TAGGG(TTAGGG)3] (Tel23) and 
d[(TTAGGG)4TT] (Tel26) that are two different truncations of human telomeric sequence; 
two sequences that occur in the nuclease hypersensitive region of the promoter of c-KIT 
oncogene d(AGGGAGGGCGCTGGGAGGAGGG) (c-kit1) and 
d(CGGGCGGGCGCGAGGGAGGGG) (c-kit2); the modified c-kit2 promoter sequence 
d(CGGGCGGGCGCTAGGGAGGGT) (c-kit2T12/T21); the c-MYC promoter sequence 
d(TGAGGGTGGGGAGGGTGGGGAAGG) (c-myc); the modified c-MYC promoter sequence 
d(TGAGGGTGGGTAGGGTGGGTAA) (Myc22) and the self-complementary duplex-forming 
dodecamer d(CGCGAATTCGCG) (ds12). The concentration of oligonucleotides was 
determined by UV adsorption measurements at 90 °C using appropriate molar extinction 
coefficient values ε (λ = 260 nm) calculated by the nearest neighbour model. Samples 
were heated at 90 °C for 5 min, and then gradually cooled to room temperature 
overnight. Parallel arrangement of telomeric sequence (Tel23-p) was prepared as 
previously described.199 
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Circular dichroism spectroscopy 
Circular dichroism (CD) experiments were recorded on a Jasco J-815 spectropolarimeter 
equipped with a PTC-423S/15 Peltier temperature controller. All the spectra were 
recorded at 20 °C in the wavelength range of 230-360 nm and averaged over 3 scans. The 
scan rate was set to 100 nm/min, with a 1 s response time, and 1 nm bandwidth. Buffer 
baseline was subtracted from each spectrum. For the CD experiments in presence of 
metal cations, 10 µM G4 DNA and 15 µM duplex DNA were used. CD spectra of 
DNA/ligand mixtures were obtained by adding 4 molar equiv. of ligands (stock solutions 
of ligands were 6 mM in DMSO). DNAs were prepared in 10 mM potassium phosphate 
(for c-kit1, Tel23 and Tel26) or 10 mM lithium phosphate (for Tel23-p and ds12) buffers 
(pH 7.0) containing 100 mM KCl. Because the Tm value of the c-myc G4 alone is above 80 
°C in buffer containing 100 mM KCl, it is very difficult to evaluate the stabilizing effects of 
adding ligands, thus a buffer solution containing lower amounts of K+ (5 mM potassium 
phosphate, 20 mM KCl) was used for the experiments on c-myc G4. As for c-kit2, it was 
shown that this sequence forms a dimeric G4 in 100 mM K+-containing solution, with a 
completely different fold compared to the monomeric G4 that is formed in buffer 
solution containing low amounts of K+. Therefore, 5 mM potassium phosphate buffer 
containing 20 mM KCl was also used in this case. 
CD melting were carried out in the 20-100 °C temperature range, at 1 °C/min heating rate 
by following changes of CD signal at the wavelengths of the maximum CD intensity. CD 
melting experiments were recorded in the absence and presence of ligands (4 molar 
equiv.) added to the folded DNA structures. For selected compounds, CD melting 
experiments were also performed by varying ligand concentration. Three different 
[ligand]/[DNA] ratio were examined (1:1, 2:1 and 4:1).The melting temperatures(Tm) were 
determined from curve fit using Origin 7.0 software.Tm values were determined as the 
difference in melting temperature between the G4-DNA with and without ligands. 
 
FRET melting studies 
FRET melting studies were performed by using the following G4 forming sequences: the 
5'-FAM-d(GGGCGGGCGCGAGGGAGGGG)-TAMRA-3' (Fckit2T) and 5'-FAM-
d(TGAGGGTGGGTAGGGTGGGTAA)-TAMRA-3' (FcmycT) oligonucleotides from the c-KIT 
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and c-MYC promoter regions, respectively; and the telomeric F21T G4-forming sequence 
were annealed at high concentrations to promote the parallel conformation (F21T-p). 
Labeled oligonucleotides were purchased from Biomers (Germany), purified employing 
standard HPLC protocols. Such studies were performed under the same buffer and 
experimental conditions used for the corresponding CD experiments. The FRET melting 
assay was carried out on a FP-8300 spectrofluorometer (Jasco) equipped with a Peltier 
temperature controller accessory (Jasco PCT-818) with excitation at 492 nm and detection 
at 522 nm. Both excitation and emission slit widths were set at 5 nm. A sealed quartz 
cuvette with a path length of 1 cm was used. The final concentration of the G4s was 0.2 
μM. The fluorescence melting of the G4s was monitored at 1 °C/min with and without 
ligands (at a 4:1 ligand/DNA ratio). Final analysis of the data was carried out using Origin 
7.0. 
 
Nuclear magnetic resonance experiments 
NMR experiments were performed on a 700 MHz Varian UnityINOVA spectrometer, with 
data recorded at 25 °C. One-dimensional proton spectra of the sample in H2O were 
recorded using pulsed-field gradient DPFGSE for H2O suppression.DNA samples were 
prepared at 0.2-0.5 mM strand concentration in 0.6 mL (H2O/D2O 9:1) buffer solution. 
NMR experiments on G4 forming oligonucleotides from c-MYC (Myc22) and c-KIT (c-
kit2T12/T21) promoters were performed employing the same buffers and experimental 
conditions as used for the determination of their 3D structures, in order to avoid different 
G4 folds or conformational heterogeneity in solution. The solution was either 25 mM 
KH2PO4, 70 mMKCl, 0.2 mM EDTA, pH 7.0 (for Myc22) or 5 mM KH2PO4, 20 mMKCl, 0.2 
mM EDTA, pH 6.8 (for c-kit2T12/T21). Aliquots of a stock solution of 3 in DMSO-d6 were 
added directly to the DNA solution inside the NMR tube. The NMR data were processed 
on an iMAC running iNMR software (www.inmr.net).  
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4.1.3. Computational studies 
Docking simulations 
The solution structures of G4 formed by the human c-kit2 promoter sequence (PDB ID: 
2KQH), and of c-myc G4 bound to quindoline molecule (PDB ID: 2L7V) were used as the 
targets for docking studies. The ligand found in the c-myc complex was removed from the 
structure to leave empty binding sites. After optimizing the ligand and assigning partial 
atomic charges, docking calculations were performed with the AutoDock 4.2 program 
using the Lamarckian genetic algorithm. The all parallel-stranded arrangement with 
propeller loops linking adjacent parallel strands on opposite surfaces of the G4s, results in 
accessible outer planar G-tetrad surfaces that, being the potenƟal binding sites for the 
ligands, were deﬁned as the grid boxes for the docking. The size of the boxes was 
constrained to 18 Å × 18 Å × 18 Å in the x, y and z dimensions. Grid maps were generated 
for each atom type in the ligand using AutoGrid. An acƟve site box was created with a grid 
spacing of 0.375 Å. The maximum number of energy evaluations was set to 2.5 × 106, the 
maximum number of genetic algorithm operations was set to 2.7 × 104, the number of 
individuals in a population was set to be 300, the rates of mutation and crossover were 
set to 0.02 and 0.8, respectively. When searching the conformational and orientation 
spaces of ligand with rotatable bonds having full flexibility, the structure of the G4 was 
kept rigid. The most favorable binding poses were selected on the basis of both the 
calculated energies and visual inspection. All the figures were drawn using VMD 1.9 
software (www.ks.uiuc.edu/Research/vmd). 
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4.1.4. Biology 
 
Cell cultures and immunofluorescence 
Human osteosarcoma U2OS and colon cancer HCT116 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Carlo Erba), supplemented with 1% L-glutamine and 
10% FBS (fetal bovine serum). U2OS cells were seeded in 35 mm dishes at a concentration 
of 100000 cell/ml. 24 h after seeding, cells were treated with 1 (2 µM and 10 µM), 3 (0.2 
µM and 1 µM), or 14a (2 µM and 10 µM). Cells were then fixed in methanol:acetic acid 
(3:1), permeabilized with 0.1% triton-X100/PBS and blocking in 2% milk/PBS. 
Immunofluorescence was performed using standard methods with BG4, anti-FLAG (Cell 
Signaling Technology) and anti-rabbit Alexa 488-conjugated (Invitrogen) antibodies. 
Nuclei were stained with DAPI (Sigma Aldrich) and coverslips were mounted with 
Mowiol® 4-88 (Sigma Aldrich). Fluorescence signal was determined using ImageJ software 
with the following formula: Corrected Total Cell Fluorescence (CTCF) = Integrate Density – 
(Area of selected cell x Mean Fluorescence of Background Readings). Significance was 
determined by parametric tests “Student’s t test”. BG4 antibody was obtained by 
transfection of BG4 plasmid (kindly obtained by S. Balasubramanian) in BL21 E. coli cells. 
Then, BG4 protein expression was induced by the autoinduction method as described by 
Studier. BG4 was purified by using silica-based resin (Protino® Ni-IDA) pre-charged with 
Ni2+ ions, eluted with 250 mM Imidazole/PBS pH 8.0. The eluted antibody was 
concentrated with Amicon Ultra-15 Centrifugal Filter Units (Millipore), and imidazole was 
finally removed by buffer exchange with PBS pH 8.0 with Amicon Ultra-15 Centrifugal 
Filter Units. 
 
MTT cell proliferation assay 
U2OS and HCT116 cells were cultured in DMEM as above, and were seeded in 24-well at a 
concentration of 40000 cell/ml. 24 h after seeding, cells were treated with the compound 
at the indicated concentration and time. After 1 h or 24 h of treatment, agents were 
removed and cells were further cultured in complete drug-free medium for 1-2 days. 
Then, thiazolyl blue tetrazolium bromide (MTT) (Sigma Aldrich) was added to each well 
and incubated for 1 h at 37 °C. Then, medium was removed and 300 µl of dimethyl 
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sulfoxide (Sigma Aldrich) was added and incubated for 1 h at room temperature. Then, 
100 µl of the solution was put in 96-well and absorbance at 595 nm was measured using a 
multiplate reader. The linear regression parameters were determined to calculate the 
IC50 (GraphPad Prism 4.0, Graph Pad Software Inc.). 
 
  
102 
 
 
4.2. Experimental data for Chapter 3 
4.2.1. Chemistry 
General methods 
1H NMR, 13C NMR and 19F NMR spectra were recorded on a Bruker AVANCE III 400 NMR 
spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) and coupling 
constants (J) are given in Hertz (Hz). Mass analyses were performed using Agilent 1200 
HPLC system coupled to Agilent G6120 single quadrupole detector equipped with an 
electrospray ionization (ESI) source in direct infusion modality. ESI-MS spectra were 
recorded in positive mode. RP (reverse phase) HPLC-MS analyses were performed with an 
Agilent 1200 HPLC system equipped with a DAD and an ESI-MS detector. HPLC conditions 
for analytical analyses: Phenomenex Luna C18 column, 5 μm, 100 Å, 250 × 4.6 mm (L × 
ID), inj. volume 20 μL, flow rate 1 mL/min. HPLC conditions for semi-preparative 
purification: Phenomenex Luna C18 column, 5 μm, 100 Å, 250 × 10.0 mm (L × ID), flow 
rate 5 mL/min. 
 
Synthesis of cCNGRC 1 
 
 
Fmoc-Cys(Acm) Wang resin (500 mg, 0.30 mmol, loading: 0.60 mmol/g) was swollen in 
DCM for 30 min and then washed with DMF. Fmoc cleavage was carried out using 20 % 
piperidine in DMF, at rt for 10 min (× 2). The resin was washed with DMF (3 × 5 mL) and 
DCM (3 × 5 mL). The coupling reaction was performed by adding to the resin a solution of 
the Fmoc-amino acid (1.5 mmol, 5 equiv), HATU (560 mg, 1.47 mmol, 4.9 equiv), DIPEA 
(0.51 mL, 3.0 mmol, 10 equiv) in DMF (5 mL), and the mixture was shaken for 2 h. The 
coupling sequence was: Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-
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Cys(Acm)-OH. Once the linear pentapeptide was assembled, the N-terminal Fmoc 
protecting group was removed. Cleavage of the pentapeptide from the resin and 
simultaneous removal of Trt and Pbf protecting groups was performed using a mixture of 
TFA/TIPS/H2O 95:2.5:2.5 v/v/v for 2 h. The cleavage mixture was drained off and the resin 
washed with TFA and DCM. The mixture was concentrated and Et2O was added to 
precipitate the crude peptide. The crude linear peptide (270 mg, 0.30 mmol, 1 equiv) was 
dissolved in AcOH (15 mL) and added dropwise over 3 h to a solution of I2 (0.12 M) in 
AcOH (150 mL) and HCl 10 M (1 mL).184 The cyclization reaction was monitored by RP-
HPLC coupled to tandem ESI-MS and stopped after 2 h by adding Et2O. The resulting 
suspension was cooled in dry-ice and then centrifuged at 5000 rpm for 3 min, decanted 
and the resulting white solid was purified by semi-preparative RP-HPLC (Solvent A: CH3CN 
0.1% TFA, Solvent B: H2O 0.1% TFA, gradient: from 1 to 7% of A in 8 min, flow 5 mL/min, 
tR= 6 min). The purified compound was lyophilized and obtained as a white powder (35 
mg, TFA salt, 15 % yield based on the estimated loading of the resin). 
1H NMR (400 MHz, D2O): δ = 4.92 (t, J = 7.2 Hz, 1H), 4.64 (dd, J = 9.9, 3.5 Hz, 1H), 4.31 (t, J 
= 7.3 Hz, 1H), 4.24 – 4.08 (m, 2H), 3.67 (d, J = 15.6 Hz, 1H), 3.40 – 3.26 (m, 3H), 3.23 (t, J = 
6.7 Hz, 2H) 3.12 (dd, J = 14.4, 9.9 Hz, 1H), 2.84 (dd, J = 15.3, 6.5 Hz, 1H), 2.72 (dd, J = 15.5, 
8.0 Hz, 1H), 1.91 – 1.61 (m, 4H); 13C NMR (101 MHz, D2O, as a TFA salt, the signal of TFA 
was not included): δ = 174.20, 173.81, 173.68, 171.57, 170.60, 167.26, 156.74, 53.61, 
52.73 (one signal for two carbons, as detected by HSQC analysis), 50.07, 42.43, 41.18, 
40.49, 40.43, 36.14, 27.22, 24.21. MS (ESI, m/z): calculated for C18H31N9O7S2 549.18; found 
550.2 [M+H]+. RP-HPLC: solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA, gradient: 
from 1 to 15% of A in 15 min, tR= 7.6 min, flow: 1 mL/min, λ=220nm. 
  
104 
 
 
Synthesis of cCNGRC-CONH2 2 
 
Fmoc protected Rink Amide MBHA resin HL (1.0 g, 0.87 mmol, loading: 0.87 mmol/g) was 
used for this synthesis. Swelling, Fmoc cleavage and washing procedures were performed 
as described above for compound 1. The coupling reactions were accomplished by adding 
to the resin a solution of the Fmoc-amino acid (1.74 mmol, 2 equiv), HATU (650 mg, 1.70 
mmol, 1.96 equiv), DIPEA (0.6 mL, 3.48 mmol, 4 equiv) in DMF (5 mL) and shaking the 
mixture for 2 h. The amino acid coupling sequence was: Fmoc-Cys(Trt)-OH, Fmoc-
Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH and Fmoc-Cys(Trt)-OH. Cleavage of the 
pentapeptide from the resin and simultaneous removal of Trt and Pbf protecting groups 
was performed using a mixture of TFA/TIPS/H2O 95:2.5:2.5 v/v/v for 2 h. The mixture was 
concentrated and Et2O was added to precipitate the crude peptide. N-chlorosuccinimide 
(60 mg, 0.45 mmol, 1 equiv) was added to the solution of the crude linear peptide (350 
mg, 0.45 mmol, 1 equiv) in H2O (20 mL) and the reaction was allowed to stir at room 
temperature for 15 min. The reaction mixture was then frozen in dry ice and freeze dried 
to obtain the crude cyclic peptide as a white powder. The crude peptide was purified by 
semi-preparative RP-HPLC (Solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA, gradient: 
from 1 to 7% of A in 7 min, flow: 5 mL/min, tR= 6.2 min) and lyophilized to give compound 
2 as a white powder (170 mg, TFA salt 25 % yield based on the estimated loading of the 
resin). 1H NMR (400 MHz, D2O): δ = 4.92 (t, J = 7.3 Hz, 1H), 4.63 (dd, J = 10.4, 3.4 Hz, 1H), 
4.31 (t, J = 7.3 Hz, 1H), 4.20 – 4.13 (m, 2H), 3.67 (d, J = 15.7 Hz, 1H), 3.38 (dd, J = 14.5, 6.8 
Hz, 1H), 3.32 (dd, J = 14.5, 3.5 Hz, 1H), 3.27 – 3.18 (m, 3H), 3.05 (dd, J = 14.5, 10.4 Hz, 1H), 
2.85 (dd, J = 15.5, 6.7 Hz, 1H), 2.73 (dd, J = 15.5, 7.9 Hz, 1H), 1.94 – 1.57 (m, 4H); 13C NMR 
(101 MHz, D2O, as a TFA salt, the signal of TFA was not included): δ = 174.24, 174.21, 
173.97, 171.62, 170.70, 167.23, 156.74, 53.50, 52.84, 52.69, 50.08, 42.40, 41.18, 40.51, 
40.44, 36.03, 27.04, 24.27. MS (ESI, m/z): calculated for C18H32N10O6S2548.19; found 549.2 
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[M+H]+. RP-HPLC: solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA, gradient: from 1 
to 15% of A in 15 min, tR= 8.0 min, flow: 1 mL/min, λ=220nm. 
 
Synthesis of Ac-cCNGRC 3 
 
The linear precursor 8 (Scheme 3.1) was assembled on the Fmoc-Cys(Acm) preloaded 
Wang resin (500mg, 0.30mmol, loading: 0.60 mmol/g) following the procedure described 
for compound 1. After Fmoc cleavage from the last amino acid, acetylation of the N-
terminus was performed on-resin adding a solution of DCM/acetic anhydride/DIPEA 
20:4:1 v/v/v (8 mL) and the resulting suspension was shaken for 1 h (repeated 2 times). 
Cleavage from the resin was carried out using a solution of TFA/TIPS/H2O 95:2.5:2.5 v/v/v 
for 2 h. The mixture was concentrated and Et2O was added to precipitate the crude 
peptide. Cyclization was performed following the procedure described for 1.184 The crude 
material was purified by semi-preparative RP-HPLC (Solvent A: CH3CN 0.1% TFA, Solvent 
B: H2O 0.1% TFA, gradient: from 10 to 15% of A in 7 min, flow: 5 mL/min, tR= 5.7 min) and 
lyophilized to give compound 3 as a white powder (65 mg, TFA salt, 30 % yield based on 
the estimated loading of the resin).1H NMR (400 MHz, D2O): δ = 4.74 (dd, J = 9.0, 3.6 Hz, 
1H), 4.65 (t, J = 7.2 Hz, 1H), 4.49 – 4.39 (m, 2H), 4.22 (d, J = 16.4 Hz, 1H), 3.73 (d, J = 16.4 
Hz, 1H), 3.33 (dd, J = 15.3, 4.4 Hz, 1H), 3.25 (t, J = 6.6 Hz, 2H), 3.21 – 3.18 (m, 1H), 3.15 
(dd, J = 7.3, 3.8 Hz, 2H), 2.93 (dd, J = 15.4, 6.6 Hz, 1H), 2.71 (dd, J = 15.4, 7.7 Hz, 1H), 2.05 
(s, 3H), 2.00 – 1.62 (m, 4H);13C NMR (101 MHz, D2O, as a TFA salt, the signal of TFA was 
not included): δ = 174.78, 174.39, 173.51, 173.41, 172.18, 172.02, 171.24, 156.73, 53.69, 
53.39, 52.60, 50.61, 42.60, 40.96, 40.54, 40.47, 35.57, 27.59, 24.31, 21.74. MS (ESI, m/z): 
calculated for C20H33N9O8S2591.19 found 592.2[M+H]+. RP-HPLC: solvent A: CH3CN 0.1% 
TFA, Solvent B: H2O 0.1% TFA, gradient: from 10 to 25% of A in 11 min tR= 6.7 min, flow 1 
mL/min, λ=220nm. 
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Synthesis of biotin-ε-Ahx-cCNGRC 4 
 
 
The linear precursor 11 (Scheme 3.2) was assembled on the Fmoc-Cys(Acm) preloaded 
Wang resin (100 – 200 mesh, 200 mg, 0,14 mmol, loading: 0.70 mmol/g) following the 
procedure described for compound 1. After Fmoc cleavage from the last amino acid, a 
solution of Fmoc-ε-Ahx-OH (250 mg, 0.70 mmol, 5 equiv), DIC (0.11 mL, 0.70 mmol, 5 
equiv) and Oxyma Pure Novabiochem® (100 mg, 0.70 mmol, 5 equiv) in DMF (3 mL) was 
added and the suspension was shaken for 2h. Then, the N-terminal Fmoc protecting 
group was removed. The cyclization step was carried out on resin by adding to the resin a 
solution of I2 (350 mg, 1.4 mmol, 10 equiv) in DMF/H2O 4/1 (v/v) (3 mL). After 4 h the 
solvent was removed and the resin was extensively washed with DMF (2 × 5 mL), 2% 
ascorbic acid in DMF (2 × 5 mL), DMF (5 × 5 mL), and DCM (3 × 5 mL). Biotin (340 mg, 1.4 
mmol, 10 equiv), DIC (0.22 mL, 1.4 mmol, 10 equiv) and Oxyma Pure Novabiochem® (200 
mg, 1.4 mmol, 10 equiv) were suspended in DMF (14 mL) at 60°C and stirred for about 40 
min until the activated biotin was completely dissolved. After cooling to room 
temperature, the reaction mixture was added to the cyclic peptide-resin and shaken for 
24 h. The resin was washed with DCM (5 x 10 mL) and DMF (5 x 10 mL). Biotin-labelled 
cyclic peptide was cleaved from the resin, along with the deprotection of the amino acid 
side chains by adding a mixture of TFA/TIPS/H2O 95/2.5/2.5 (v/v/v) for 2 h. The mixture 
was concentrated and Et2O was added to precipitate the crude peptide. The crude was 
dissolved in H2O, purified by semi-preparative RP-HPLC (Solvent A: CH3CN 0.1% TFA, 
Solvent B: H2O 0.1% TFA, gradient: from 10 to 35% of A in 15 min, flow 5 mL/min, tR=7 
min) and lyophilized to give compound 4 as a white powder (9.6 mg, TFA salt, 7 % yield 
based on estimated loading of the resin). 1H NMR (400 MHz, D2O): δ = 4.66 – 4.57 (m, 2H), 
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4.50 (dd, J = 8.4, 5.9 Hz, 1H), 4.46 – 4.35 (m, 2H), 4.22 (d, J = 16.3 Hz, 1H), 4.00 – 3.96 (m, 
1H), 3.72 (d, J = 16.4 Hz, 1H), 3.39 – 2.77 (m, 12H), 2.71 (dd, J = 15.5, 7.5 Hz, 1H), 2.40 – 
2.23 (m, 4H), 1.96 – 1.30 (m, 16H). MS (ESI, m/z): calculated for C34H56N12O10S3 888.34; 
found 889.3 [M+H]+. RP-HPLC: solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA, 
gradient: from 5 to 50 % of A in 15 min, tR= 10.46 min, flow: 1 mL/min, λ=220nm. 
 
Synthesis of S-methoxytrityl-cysteine 18 
 
 
To a stirred suspension of anhydrous L-cysteine (1 g, 8,25 mmol, 1 equiv) in 8 mL of AcOH 
was added 4-methoxytrityl alcohol (2,8 g, 9,65 mmol, 1.17 equiv). BF3-etherate 1,8 mL 
was then added gradually in order to mantain the reaction mixture at 25 °C. An intense 
brown coloration developed and the suspended solid dissolved as the addition 
progressed. The reaction mixture was allowed to react for 2 h and to the solution was 
then added, with ice-cooling, 20 mL of saturated aqueous AcONa and 45 mL of H2O. The 
mixture was stirred for 10-15 minutes and allowed to stand at 0 °C. The resulting 
gelatinous white solid was collected by decantation and then treated with Et2O to achieve 
the precipitation of a white powder. Et2O was then removed by filtration and the solid 
was then washed several times with Et2O to obtain the pure S-methoxytrityl-cysteine 18 
(3,1 g, quantitative yield). 1H NMR (400 MHz, CD3OD) δ = 7.43 (d, J = 7.7 Hz, 4H), 7.36 – 
7.15 (m, 8H), 6.84 (d, J = 8.9 Hz, 2H), 3.75 (s, 3H), 3.10 (dd, J = 8.7, 3.9 Hz, 1H), 2.82 (dd, J 
= 13.3, 3.9 Hz, 1H), 2.71 (dd, J = 13.2, 9.1 Hz, 1H). 
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Synthesis of Boc-Cys(Mmt)-OH 
 
 
To a solution of S-methoxytrityl-cysteine 18 (3,3 g, 8,8 mmol, 1 equiv) in 50% saturated 
aqueous NaHCO3, Na2CO3 (0,9 g, 8,8 mmol, 1 equiv) was added and the resulting 
suspension was cooled at 0 °C. A solution of Boc2O (1,9 g, 8,8 mmol, 1 equiv) in 1,4-
dioxane 4 mL was then added and the reaction mixture was allowed to react at 0 °C for 30 
min and at room temperature for 20 h. The mixture was washed with Et2O to remove the 
excess of Boc2O. The aqueous layer was treated with HCl 2N till pH = 4 and extracted with 
EtOAc (3 x 50 mL). The combined organic layers were dried over MgSO4 and evaporated 
under reduced pressure to obtain a pure white solid (3,3 g, 82 % yield). 1H NMR (400 
MHz, CD3OD): δ = 7.38 (d, J = 7.6 Hz, 4H), 7.27 (t, J = 7.5 Hz, 6H), 7.23 – 7.16 (m, 2H), 6.84 
(d, J = 9.0 Hz, 2H), 4.05 (t, J = 6.2 Hz, 1H), 3.78 (s, 3H), 2.56 (d, J = 6.3 Hz, 2H), 1.44 (s, 9H). 
 
Synthesis of cCNGRCKG-biotin 5 
 
 
The linear peptide 15 was assembled on an Fmoc protected Rink Amide MBHA resin HL 
(1.0 g, 0.87 mmol, loading: 0.87 mmol/g) following the procedure already described for 
compound 2. The amino acid coupling sequence was Fmoc-Gly-OH, Fmoc-Lys(Dde)-OH, 
Fmoc-Cys(Mmt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Boc-Cys(Mmt)-
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OH. Once the linear heptapeptide 15 was assembled, Dde removal was achieved using a 
solution (10 mL) of NH2NH2(2%) in DMF for 3 min (× 2). Biotin (420 mg, 1.74 mmol, 2 
equiv) was dissolved in DMF (8 mL) and the solution warmed at 80 °C in order to 
solubilize the solid powder. Once biotin was completely solubilized, the mixture was 
cooled to rt before adding HATU (650 mg, 1.70 mmol, 1.96 equiv) and DIPEA (0.6 mL, 3.48 
mmol, 4 equiv). The mixture was added to the resin and the suspension was shaken for 2 
h. The coupling was repeated twice. Cleavage of the biotin labelled peptide 16 from the 
resin and simultaneous removal of Mmt, Trt and Pbf protecting groups was performed 
using a mixture of TFA/TIPS/H2O 95:2.5:2.5 v/v/v for 2 h. The mixture was concentrated 
and Et2O was added to precipitate the crude peptide. The crude peptide (860 mg,0.72 
mmol) was dissolved in 50 mM phosphate buffer, pH 7.4 (250 mL) and the reaction was 
stirred bubbling air through it. The disulphide bridge formation was monitored by RP-
HPLC coupled to tandem ESI-MS and it was complete after 72 h. The aqueous medium 
was concentrated under reduced pressure and the resulting precipitate was filtrated and 
washed several times with H2O and CH3CN. Compound 5 was obtained as a pure white 
powder 400 mg, 48% yield, based on the estimated loading of the resin).1H NMR (400 
MHz, D2O): δ = 4.79 (overlapped with solvent signal, 1H, as detected by COSY and HSQC 
experiments) 4.66 – 4.59 (m, 2H), 4.44 (dd, J = 7.7, 4.5 Hz, 1H), 4.40 – 4.34 (m, 1H), 4.31 
(dd, J = 8.4, 5.5 Hz, 1H), 4.15 (d, J = 16.0 Hz, 1H), 3.96 (d, J = 17.1 Hz, 1H), 3.90 (d, J = 17.1 
Hz, 1H), 3.75 (d, J = 16.2 Hz, 1H), 3.70 (br, 1H), 3.40 – 2.73 (m, 13H), 2.27 (t, J = 7.0 Hz, 
2H), 1.96 – 1.30 (m, 16H). MS (ESI, m/z): calculated for C36H61N15O10S3 959.39; found ESI-
MS: m/z 960.3 [M+H]+. RP-HPLC: solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA, 
gradient: from 5 to 40 % of A in 11 min, tR= 8.2 min, flow: 1 mL/min, λ=220nm. 
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Synthesis of Ac-cCNGRCKG-biotin 6 
 
 
 
 
Compound 5 (15 mg, 15.6 µmol, 1 equiv) was dissolved in water (2.5 mL) and treated with 
acetic anhydride (5.0 µL, 52.9 µmol, 3.4 equiv) at rt for 10 min. The crude peptide was 
purified by semi-preparative RP-HPLC (Solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% 
TFA, gradient: from 5 to 50 % of A in 15 min, flow: 5 mL/min, tR= 10.8 min) and lyophilized 
to give compound 6 as a white powder (17mg, quantitative yield). 1H NMR (400 MHz, 
D2O): δ = 4.70 – 4.61 (m, 3H), 4.52 (t, J = 7.1 Hz, 1H), 4.46 – 4.38 (m, 2H), 4.31 (dd, J = 8.7, 
5.5 Hz, 1H), 4.20 (d, J = 16.4 Hz, 1H), 3.96 (d, J = 17.2 Hz, 1H), 3.89 (d, J = 17.3 Hz, 1H), 3.73 
(d, J = 16.3 Hz, 1H), 3.38 – 3.09 (m, 9H), 3.01 (dd, J = 13.0, 4.9 Hz, 1H), 2.93 (dd, J = 15.5, 
6.5 Hz, 1H), 2.83 – 2.70 (m, 2H), 2.27 (t, J = 7.1 Hz, 2H), 2.06 (s, 3H), 1.95 – 1.36 (m, 16H); 
13C NMR (101 MHz, D2O): δ = 176.63, 174.66, 174.27, 174.25, 173.90, 173.59, 172.11, 
171.89, 171.79, 171.44, 165.30, 156.71, 62.10, 60.25, 55.46, 54.03, 53.45, 53.42, 53.20, 
50.50, 42.76, 42.03, 40.99, 40.53, 40.33, 39.70, 38.92, 35.64, 35.46, 30.33, 27.87, 27.80, 
27.67, 27.51, 25.17, 24.40, 22.45, 21.73.MS (ESI, m/z): calculated for 
C38H63N15O11S31001.4; found 1002.4 [M+H]+. RP-HPLC: solvent A: CH3CN 0.1% TFA, 
Solvent B: H2O 0.1% TFA, gradient: from 5 to 50 of A in 15 min, tR= 10.5 min, flow: 1 
mL/min, λ=220nm. 
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Synthesis of 5(6)-carboxy-2′,7′-difluorofluorescein (Oregon green 488) 
 
OHO
F F
O
5(6)-carboxy-2',7'-difluorofluorescein
HOOC
O
O
 
 
Trimetillic anhydride (750 mg, 3.9 mmol, 1 equiv) was added to a 1M solution of 4-
fluororesorcinol (1 g, 7.8 mmol, 2 equiv) in methanesulfonic acid (7.8 mL). The resulting 
mixture was heated under dry nitrogen at 80 °C for 24 h. The cooled mixture was poured 
into 7 volumes of ice water and the resulting precipitate was filtrated, washed with H2O, 
dried at 60 °C in vacuo to give 5(6)-carboxy-2′,7′-difluorofluorescein as an orange powder 
(a mixture of 5 and 6 regioisomers was obtained according to ref. 190) (1.6 g, quantitative 
yield). 1H NMR (400 MHz, CD3OD) δ 8.64 (s, 1H), 8.42 (dd, J = 8.0, 1.5 Hz, 1H), 8.35 (dd, J = 
8.0, 1.3 Hz, 1H), 8.14 (d, J = 7.7 Hz, 1H), 7.79 (s, 1H), 7.36 (d, J = 8.0 Hz, 1H), 6.90−6.85 (m, 
4H), 6.46 (d, J = 10.2 Hz, 4H); 19F NMR (376 MHz, DMSO-d6) δ −139.69, −139.73. 
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Synthesis of cCNGRCKG-OG 7 
 
 
isomer b
7
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NovaPEG Rink Amide resin (1.0 g, 0.49 mmol, loading: 0.49 mmol/g) was used for the 
synthesis of the linear peptide 15. Swelling, Fmoc cleavage and washing of the resin were 
performed as described for compound 1. The coupling reaction was performed by adding 
to the resin a solution of the Fmoc-aa (2.45mmol, 5 equiv), HATU (913 mg, 2.4 mmol, 4.9 
equiv), DIPEA (0.8 mL, 4.9mmol, 10 equiv) in DMF (5 mL), and the mixture was shaken for 
2 h. The amino acid coupling sequence was Fmoc-Gly-OH, Fmoc-Lys(Dde)-OH, Fmoc-
Cys(Mmt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Boc-Cys(Mmt)-OH. 
After assembling the linear peptide, the Dde removal was achieved as described for 
compound 5 and the fluorescent probe OG (as a mixture of 5 and 6 regioisomers) was 
then coupled by adding to the resin the solution of OG (404 mg, 0.98 mmol, 2 equiv), 
HATU (365 mg; 0.96 mmol, 1.96 equiv) and DIPEA (0.33 mL, 1.96 mmol, 4 equiv) in DMF 
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(6 mL) and the resulting red suspension was shaken for 2 h. The resin was extensively 
washed with DMF (3 x 5 mL), DCM (3 x 5 mL), MeOH containing 0.1% NH4OH conc. (10 x 5 
mL). Cleavage of the OG labelled peptide 17 from the resin and simultaneous removal of 
Mmt, Trt and Pbf protecting groups were performed using a mixture of TFA/TIPS/H2O 
95:2.5:2.5 v/v/v for 2 h. The mixture was concentrated and Et2O was added to precipitate 
the crude peptide. N-chlorosuccinimide (53 mg, 0.4 mmol, 1 equiv) was added to the 
solution of the crude linear peptide (540 mg, 0.4mmol, 1 equiv) in H2O/CH3CN 9:1 (40 mL) 
and the reaction was allowed to stir at room temperature for 15 min. The reaction 
mixture wan then frozen in dry ice and freeze dried to obtain the crude cyclic peptide as 
an orange powder. The crude peptide was purified by semi-preparative RP-HPLC (Solvent 
A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA, gradient: 26 % of A in 7 min, flow: 5 
mL/min, isomer A, tR= 5.6 min; isomer B, tR= 6.1 min) and lyophilized to give compound 7 
isomer A and isomer B as an orange powder (180 mg, TFA salt, 25% yield based on the 
estimated loading of the resin). Isomer A): 1H NMR (400 MHz, D2O) δ = 8.45 (s, 1H), 8.10 – 
8.03 (m, 1H), 7.34 – 7.25 (m, 1H), 6.82 – 6.75 (m, 2H), 6.67 – 6.56 (m, 2H), 4.91 (t, J= 7.1 
Hz, 1H), 4.60 (dd, J = 8.9, 2.8 Hz, 1H), 4.40 – 4.31 (m, 1H), 4.26 – 4.16 (m, 2H), 4.11 (d, J = 
15.8 Hz, 1H), 3.95(d, J = 17.6 Hz, 1H), 3.88 (d, J = 17.2 Hz, 1H), 3.65 (d, J = 15.6 Hz, 1H), 
3.47 – 2.98 (m, 8H), 2.83 (dd, J = 15.3, 6.3 Hz, 1H), 2.73 (dd, J = 15.5, 7.7 Hz, 1H), 1.98 – 
1.36 (m, 10H); 19F NMR (376 MHz, D2O) δ = −75.55 (TFA signal), −134.87. Isomer B): 1H 
NMR (400 MHz, D2O) δ = 8.10 (d, J = 6.8 Hz, 1H), 7.96 (d, J = 6.5 Hz, 1H), 7.54 (s, 1H), 6.80 
– 6.77 (m, 2H), 6.56 (s, 2H), 4.91 (t, J = 7.1 Hz, 1H), 4.58 (dd, J = 9.1, 3.6 Hz, 1H), 4.27 – 
4.16 (m, 3H), 4.11 (d, J = 15.7 Hz, 1H), 3.91(d, J = 17.2 Hz, 1H), 3.84 (d, J = 17.2 Hz, 1H), 
3.65 (d, J = 15.7 Hz, 1H), 3.40 – 2.98 (m, 8H), 2.84 (dd, J = 15.6, 6.4 Hz, 1H), 2.73 (dd, J = 
15.5, 7.8 Hz, 1H), 1.82 – 1.26 (m, 10H); 19F NMR (376 MHz, D2O) δ = −75.55 (TFA signal), 
−134.87. MS (ESI, m/z): calculated for C47H55F2N13O14S2 1127.34; found 1128.4 [M+H]+. 
RP-HPLC: solvent A: CH3CN 0.1% TFA, Solvent B: H2O 0.1% TFA, gradient: from 10 to 60% 
of A in 15 min, isomer A, tR= 9.9 min; isomer B, tR= 10.2 min, flow: 1 mL/min, λ=480nm. 
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4.2.2. Biology 
In vitro APN inhibition assay. 
IC50 values against APN were determined using L-leucine-p-nitroanilide as substrate and 
microsomal aminopeptidase from porcine kidney (pAPN, Sigma) (15 units/mg protein). 
The assay was performed in a 96-well plate in Phosphate Buffer Saline (PBS, KH2PO4 1.47 
mM, Na2HPO4 7.8 mM, NaCl 137 mM, KCl 2.7 mM, CaCl2 1.8 mM, MgCl2 1.8 mM), pH 7.2, 
at 37 °C. Bestatin was used as a positive control, while biotin was used as a negative one. 
0.5 μg/mL pAPN and 250 µM L-leucine-p-nitroanilide were incubated in 100 μL of PBS, pH 
7.2 in the presence of gradient concentrations of inhibitor (the concentration of peptides 
1–6 and biotin ranged from 5 μM to 2.5 mM, while the concentration of bestatin from 50 
nM to 25 μM). The assay mixture was incubated at 37°C for 1 h. Formation of the product 
p-nitroaniline was monitored by following the change in the absorbance measured at 405 
nm with the UV-Vis spectrophotometer (Synergy HT, BioTek).The IC50 value was defined 
as the concentration of each peptide that led to 50 % of maximal pAPN catalytic activity. 
 
Cell culture. 
Human fibrosarcoma HT1080 cells were cultured in Dulbecco’s Modified Essential 
Medium (Invitrogen) containing 9% fetal bovine serum (SIGMA) and incubated at 37°C in 
a humidified atmosphere containing 5% CO2 and passed twice a week.  
 
Inhibitory assay on HT1080 cells. 
One day prior the experiment, HT1080 cells from a confluent plate were detached using 
trypsin/EDTA (Invitrogen) and plated at a 70% confluency in 96 well plate (approximately 
60,000 cell/well). 24 hours later the cells were washed twice in PBS and incubated in 100 
µl of PBS containing 250 µM APN substrate L-leucine-p-nitroanilide) and the different 
compounds at the indicated concentration. The cells were then incubated for 1.5 h at 
37°C and absorbance at 405 measured every 10 minutes. 
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Binding curve of Fluorescent cCNGRCKG-OG 7 on HT1080 cells. 
One day prior the experiment, HT1080 cells from a confluent plate were detached using 
trypsin/EDTA (Invitrogen) and plated at a 20% confluency in 96 well plate (approximately 
20,000 cell/well). After 24 hours the cells were incubated for 60 min on ice with 
increasing concentration of compound 7. After incubation the cells were washed three 
times in PBS and fixed in paraformaldehyde (3.7% in PBS) for 15 minutes, washed three 
times in PBS and imaged at 20 × magnification. For each field both a DIC and a fluorescent 
channel were collected. 
 
Displacement of Fluorescent cCNGRCKG-OG 7 on HT1080 cells. 
One day prior the experiment, HT1080 cells from a confluent plate were detached using 
trypsin/EDTA (Invitrogen) and plated at a 20% confluency on glass coverslips 
(approximately 20,000 cell/well). After 24 h the cells were incubated for 60 min on ice 
with compound 7 (40 µM) in absence or in presence of bestatin (100 µM) or compound 5 
(1 mM). After incubation the cells were washed three times in PBS and fixed in 
paraformaldehyde (3.7% in PBS) for 15 minutes, washed three times in PBS and imaged at 
40 × magnification. For each field both a DIC and a fluorescent channel were collected. 
 
Quantification of fluorescence on cells. 
The microscopic fields were acquired using the same settings and exposure time for all 
the images and we ensured that all the pixels in the images were in the dynamic range of 
the detector (saturated pixels < 0.1 %). The images were then analyzed using ImageJ open 
source software. The outline of the cells were manually traced using the DIC channel. The 
outlines of the cells were then superimposed to the fluorescent channel and the 
fluorescence of each single cell was measured. For each condition we measured at least 
120 cells.  
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Abbreviations  
Ac: acetyl 
AcOH: acetic acid 
ACN:acetonitrile 
Acm: acetamidomethyl 
APN, CD13: aminopeptidase N 
Arg, R: arginine 
Asn, N: asparagine 
Boc: tert-butyloxycarbonyl 
Boc2O: di-tert-butyl dicarbonate 
CD: circular dichroism 
cCNGRC: cyclic Cys-Asn-Gly-Arg-Cys peptide 
Cy 5.5: cyanine 5.5 fluorescent dye 
Cys, C: cysteine 
d: deuterium 
DCM: dichloromethane 
Dde: N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl) 
DIPEA: N,N’-diisopropylethylamine 
DIC: N,N′-diisopropylcarbodiimide 
DMEM: Dulbecco’s Modified Eagle Medium  
DMF: N,N-dimethylformamide 
DMSO-d6 : hexadeuterodimethyl sulfoxide 
ECM: extracellular matrix protein 
Et2O: diethyl ether 
EtOAc: ethyl acetate 
FBS: fetal bovine serum 
Fmoc: fluorenylmethyloxycarbonyl 
Fmoc-ε-Ahx-OH: Fmoc-6-aminohexanoic acid 
FRET: fluorescence resonance energy transfer  
G4: G-quadruplex  
GIST: gastrointestinal stromal tumors  
Gly, G: glycine 
HAT: histone acetyltransferase  
HATU: 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HIF: hypoxia inducible factors  
hTER: telomere reverse transcriptase  
Lys, K: lysine 
MRI: magnetic resonance imaging 
Mmt: (4-methoxyphenyl)diphenylmethyl 
NCS: N-chlorosuccinimide 
NHE: nuclease hypersensitivity element  
NMR: nuclear magnetic resonance  
OG 488:Oregon Green, 5(6)-carboxy-2′,7′-difluorofluorescein 
Pbf: 2,2,4,6,7-pentamethyldihydrobenzofurane 
r.t.: room temperature  
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THP: tumor-homing peptide 
TFA: trifluoroacetic acid 
Trt: trityl 
TIPS: triisopropylsilane 
VEGF: vascular endothelial growth factor  
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Appendix 
NMR spectra of compounds described in Chapter 2 
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